

2 ACKNOWLEDGMENTS

3

Members of the Working Group are acknowledged for their valuable contribution to this
Opinion. The members of the Working Group are:

7	The SCCS members:	
8	Dr U. Bernauer	(Chairperson and co-rapporteur)
9	Dr L. Bodin	
10	Prof. Q. Chaudhry	(co-rapporteur)
11	Prof. P.J. Coenraads	
12	Dr E. Gaffet	
13	Prof. E. Panteri	
14	Dr M. Stepnik	
15	Dr S. Wijnhoven	
16 17	The SCHEER members	
18	Dr W.H. de Jong	
19	Di Willi de Jong	
20	External experts	
21	Dr N. von Goetz	
22	Dr H. Louro	
23		
24		
25		
26	All Declarations of Working	Group members are available on the following webpage:
27	-	pert groups and other similar entities
28		sere groups and other similar encicles
29		
30		
31		
32		
33		
34		
35		
36		
37		
38 39		
39 40		
40 41		
42		
42 43		
44		
45		
46		
40		

2 1. ABSTRACT

3

5

16

4 The SCCS concludes the following:

- In light of the data provided, does the SCCS consider safe the use of Titanium Dioxide
 (nano) coated with a combination of w/w 6% Aluminium Hydroxide, 14% Sodium
 Myristoyl Sarcosinate and 10% Dimethicone, for use as UV filter in dermally applied
 cosmetic products?
- Considering all the provided information, the SCCS is of the view that there are a number of uncertainties and data gaps that do not allow a conclusion on the safety of titanium dioxide (nano) coated with a combination of w/w 6% aluminium hydroxide, 13 14% sodium myristoyl sarcosinate and 10% dimethicone (Eclipse 70) - either on the basis of a similarity to the TiO₂ nanomaterials previously assessed by the SCCS, or on the basis of the additional information provided in the current submission.
- Does the SCCS have any further scientific concerns regarding the use of Titanium
 Dioxide (nano) coated with the above-mentioned materials when used as UV-filter in
 dermally applied cosmetic products?
- 20 The provided information has not demonstrated a similarity of the titanium dioxide with the above-mentioned composite coating (Eclipse 70) to other TiO₂ nanomaterials 21 22 assessed in the previous SCCS Opinion (SCCS/1516/13 - Revision of 22 April 2014) in 23 terms of physicochemical characteristics, stability of the coating, and the lack of dermal absorption of the nanoparticles. If these aspects cannot be addressed, 24 25 additional data on physicochemical, toxicological and exposure aspects specifically 26 relating to the nanomaterial under evaluation (Eclipse 70) will be needed to conclude 27 on the safety of its use in cosmetic products.
- 28
- 29
- 30
- 31
- 32
- 33
- 55
- 34 35
- 55
- 36
- 37
- 38
- 39
- Keywords: SCCS, scientific opinion, TiO₂, coatings, nano, CAS/EC numbers 13463-67-7/236675-5, 1317-70-0/215-280-1, 1317-80-2/215-282-2, Regulation 1223/2009

42

- Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on Opinion
 on new coating for Titanium Dioxide (nano form), 20 May 2024, SCCS/1667/24
- 45

1		
2 3 4 5 6 7 8 9	About the Scientific Committees Two independent non-food Scientific Committee advice it needs when preparing policy and proper and the environment. The Committees also dr emerging problems which may pose an actual They are: the Scientific Committee on Consume on Health, Environmental and Emerging Risk appointed in their personal capacity.	osals relating to consumer safety, public health aw the Commission's attention to the new or or potential threat. er Safety (SCCS) and the Scientific Committee
10 11 12	In addition, the Commission relies upon the (EFSA), the European Medicines Agency (EMA) and Control (ECDC) and the European Chemica	, the European Centre for Disease Prevention
13 14 15 16 17 18 20 21 22 23 24 25 26 27	SCCS The Committee shall provide Opinions on quest risks (notably chemical, biological, mechanical a products (for example: cosmetic products ar personal care and household products such as tattooing, artificial sun tanning, etc.). Scientific Committee members Ulrike Bernauer, Laurent Bodin, Qasim Chaudhr Gaffet, Corrado Lodovico Galli, Eirini Panteri, Stepnik, Tamara Vanhaecke, Susan Wijnhoven Contact European Commission Health and Food Safety	and other physical risks) of non-food consumer nd their ingredients, toys, textiles, clothing, detergents, etc.) and services (for example: ry, Pieter Jan Coenraads, Janine Ezendam, Eric
28 29 30 31	Directorate B: Public Health, Cancer and Health Unit B3: Health monitoring and cooperation, He L-2920 Luxembourg <u>SANTE-SCCS@ec.europa.eu</u>	
28 29 30	Unit B3: Health monitoring and cooperation, H L-2920 Luxembourg	
28 29 30 31	Unit B3: Health monitoring and cooperation, He L-2920 Luxembourg <u>SANTE-SCCS@ec.europa.eu</u> © European Union, 2024	
28 29 30 31 32	Unit B3: Health monitoring and cooperation, He L-2920 Luxembourg <u>SANTE-SCCS@ec.europa.eu</u> © European Union, 2024	ealth networks BN
28 29 30 31 32 33 34 35 36 37 38 39	Unit B3: Health monitoring and cooperation, He L-2920 Luxembourg <u>SANTE-SCCS@ec.europa.eu</u> © European Union, 2024 ISSN IS	ealth networks BN D nt the views of the independent scientists who necessarily reflect the views of the European
28 29 30 31 32 33 34	Unit B3: Health monitoring and cooperation, He L-2920 Luxembourg SANTE-SCCS@ec.europa.eu © European Union, 2024 ISSN IS Doi NI The opinions of the Scientific Committees prese are members of the committees. They do not Commission. The opinions are published by	ealth networks BN D nt the views of the independent scientists who necessarily reflect the views of the European the European Commission in their original

1 2		TABLE OF CONTENTS
3	ACKNOWLEDGMEN	TS2
4	1. ABSTRACT	
5	2. MANDATE FR	OM THE EUROPEAN COMMISSION6
6	3. OPINION	
7	3.1 CHEMI	CAL AND PHYSICAL SPECIFICATIONS
8 9 10 11 12 13 14 15 16 17 18 20 21 22 23 22 23 24 25	3.1.1 3.1.2 3.1.3 3.1.4 3.1.5 3.1.6 3.1.7 3.1.8 3.1.9 3.1.10 3.1.11 3.1.12 3.1.13 3.1.14 3.1.15 3.1.16 3.1.17 3.2 TOXICO	Chemical identity8Physical form10Molecular weight11Purity, composition and substance codes11Impurities / accompanying contaminants12Solubility13Partition coefficient (Log Pow)13Additional physical and chemical specifications13Particle size14Microscopy15Crystal structure19UV absorption20Surface characteristics21Droplet size in formulations21Homogeneity and stability21Other parameters of characterisation22Summary on supplementary physicochemical characterisation22DKINETICS23
26 27 28	3.2.1 3.2.2 3.3 EXPOS	Dermal / percutaneous absorption
29 30	3.3.1 3.4 TOXICO	Function and uses31DLOGICAL EVALUATION31
31	3.5 SAFETY	VEVALUATION (INCLUDING CALCULATION OF THE MOS)
32	3.6 DISCU	SSION
33 34 35	5. MINORITY O	40 PINION
36 37 38 39 40 41 42 43 44 45 46		

2 2. MANDATE FROM THE EUROPEAN COMMISSION

3 Background

5 Titanium Dioxide, TiO₂, (CAS/EC numbers 13463-67-7/236-675-5, 1317-70-0/215-280-1, 6 1317-80-2/215-282-2) is authorized both as colorant under entry 143 of Annex IV, as UV-7 filter under entry 27 of Annex VI, and in powder form in entry 321 of Annex III to Regulation 8 (EC) No 1223/2009.

9

In July 2013¹, the Scientific Committee on Consumer Safety (SCCS) issued the safety evaluation on Titanium Dioxide (nano) concluding that the use of Titanium Dioxide (nano) as UV-filter, at concentrations up to 25 % and with the characteristics indicated in the opinion, can be considered not to pose any risk of adverse effects in humans after application on healthy, intact or sunburnt skin. Among the characteristics reported in that opinion, the SCCS indicated the substances considered safe for use as coating for TiO₂ (nano). Regarding the use of other coatings, not covered in the opinion, the SCCS concluded that:

17

18 'Other cosmetic ingredients applied as stable coatings on TiO₂ nanomaterials can also be used,
19 provided that they can be demonstrated to the SCCS to be safe and the coatings do not affect
20 the particle properties related to behaviour and/or effects, compared to the nanomaterials
21 covered in this opinion'.

The SCCS conclusion clarifies that for the use of a substance as coating on TiO₂ nanomaterials, the applicant has to demonstrate that properties/behaviour of the particles with the new coating are not significantly different compared to those already covered in the SCCS opinion. This would need provision of data on physico-chemical properties (in line with those provided in Tables 1-3 of the SCCS/1516/13 opinion), and data on dermal penetration.

28

In August 2023, the Commission' services received a dossier related to a new nano-form of TiO₂ material (i.e., Eclipse 70) coated with 'Aluminium Hydroxide', 'Sodium Myristoyl Sarcosinate' and 'Dimethicone'. 'Aluminium Hydroxide' and 'Dimethicone' coatings were already assessed by SCCS in 2014, while 'Sodium Myristoyl Sarcosinate' coating has not yet been assessed.

The Commission requests the SCCS to carry out a safety assessment on 'Sodium Myristoyl Sarcosinate' (CAS No. 30364-51-3/ EC No. 250-151-3) as a coating of Titanium Dioxide (nano) in view of the information provided.

¹ SCCS (Scientific Committee on Consumer Safety), Opinion on 56 titanium dioxide (nano form), 22 July 2013, revision of 22 April 2014

1. In light of the data provided, does the SCCS consider safe the use of Titanium Dioxide (nano) coated with a combination of w/w 6% Aluminium Hydroxide, 14% Sodium Myristoyl

Sarcosinate and 10% Dimethicone, for use as UV filter in dermally applied cosmetic products?

Terms of reference

1

8

9

10 11

2. Does the SCCS have any further scientific concerns regarding the use of Titanium Dioxide (nano) coated with the above-mentioned materials when used as UV-filter in dermally applied 12 cosmetic products?

13

3. OPINION

Preamble

5 6 As indicated in section 2 (Background), the SCCS can consider the use of a new coating on 7 TiO_2 nanomaterials safe, if the properties/behaviour of the particles with the new coating are 8 demonstrated to be not significantly different compared to those already covered in the SCCS 9 opinion (SCCS/1516/13). For this, data need to demonstrate that a TiO_2 nanomaterial with the new coating has a comparable profile in terms of physicochemical properties (in line with 10 those provided in Tables 1-3 of the previous Opinion SCCS/1516/13-Revision of 22 April 11 12 2014), the new coating is stable, and that dermal penetration has not changed as a result of 13 the new coating.

14

26 27 28

29 30

31 32

33

36 37 38

43 44

45 46

47

1 2

3 4

The submission under current evaluation relates to a TiO₂ nanomaterial (Eclipse 70-D13-NT-77891, abbreviated as Eclipse 70) that has a composite surface coating made of 3 substances – an inner layer of aluminium hydroxide on to the surface of TiO₂ nanoparticles; followed by sequential layers of sodium myristoyl sarcosinate and dimethicone.

During the process of evaluation, the SCCS raised a request for further information on a number of aspects relating to the submission. The replies received from the Applicant in response to the SCCS request have also been taken into consideration in this Opinion.

The Tables and Figures included in this Opinion have been renumbered by the SCCS to follow a sequence.

3.1 CHEMICAL AND PHYSICAL SPECIFICATIONS

3.1.1 Chemical identity

3.1.1.1 Primary name and/or INCI name

34 Provided by the Applicant:35

Chemical identity of ECLIPSE 70

Description: Amino acid-treated nano titanium dioxide with dimethicone

39
40 Core material: TITANIUM DIOXIDE (nano form)
41 Coating materials: ALUMINUM HYDROXIDE (and) SODIUM MYRISTOYL SARCOSINATE (and) DIMETHICONE

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

3.1.1.2 Chemical names


48 **Provided by the Applicant:**

50	Core material:	Titanium dioxide (nano form); Titanium (IV) oxide					
51	Coating materials:	Aluminium hy	Aluminium hydroxide				
52		Sodium	myristoyl	sarcosinate:	sodium;2-		
53		[methyl(tetra	adecanoyl)amino] ad	cetate			
54		Dimethicone:	dimethyl-bis(trime	thylsilyloxy)silane			
55							
56			Ref.: 0. ⁻	TM_Eclipse 70 DOSSIE	R_06Aug23.pdf		

3.1.1.3 Trade name	s and abbreviations
Provided by the Ap	plicant:
	-
ECLIPSE/0-D13-N1-/	77891 (abbreviated as 'Eclipse 70')
	Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.
3.1.1.4 CAS / EC nu	mber
Provided by the Ap	plicant:
Core material:	Titanium dioxide (nano form) - CAS No. 13463-67-7; EC No. 236-6 5
Coating materials:	Aluminium hydroxide - CAS No. 21645-51-2; EC No. 244-492-7 Sodium myristoyl sarcosinate - CAS No. 30364-51-3; EC No. 250-1
	3 Dimethicone - CAS No. 63148-62-9; EC No. not available
	Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.
3.1.1.5 Structural fo	prmula
Provided by the Ap	plicant:
Core material:	Titanium dioxide
Coating materials:	Aluminium hydroxide:
	8
	0-Al
	ò
	Sodium myristoyl sarcosinate:
	Dimethicone
	Si o Si Si
	77001 obbrowisted as \Ealines 70/ consists of an ansing a sid tweated as
titanium dioxide cor	77891, abbreviated as 'Eclipse 70' consists of an amino-acid treated name (TiO ₂ ; up to 70% w/w) coated with the following materials: (up to 6% w/w), 2) sodium myristoyl sarcosinate (up to 14% w/w), and 10% w/w).

43 The structure is shown in **Figure 1**:

- Aluminium hydroxide (in blue) forms a layer around the central titanium dioxide particles.
 The original composite alumina coating is characterized by a dense portion and a hydrated
 - The original composite alumina coating is characterized by a dense portion and a hydrated portion (boehmite).
 - The green filaments represent the sodium myristoyl sarcosinate moieties, chemically bound to the titanium dioxide particles via the aluminium hydroxide.
- 6 The yellow planes correspond to the dimethicone coating, which is bound to the particle via amino acid chains.



12

13

27 28

3 4 5

10 **Figure 1:** Schematic representation of Eclipse 70 11

From Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

14 SCCS comment

In the submission, CAS number 63148-62-9 has been quoted for one of the coating materials (dimethicone), with the assertion that it has already been assessed as a coating material in a previous SCCS Opinion. The SCCS however noted that dimethicone (dimethylpolysiloxane) is a silicone polymer that as such does not have an assigned discrete chemical formula/structure, and the chemical formula/structure and molecular weight quoted in the submission all belong to another discrete compound 'dimeticone' (octamethyltrisiloxane; CAS Number: 28349-86-2).

In response to the SCCS request for further information, the Applicant confirmed that it was dimethicone that was used as one of the components of the coating. This means that the information provided in the submission relating to chemical formula, structure, molecular weight needs to be corrected.

29	3.1.1.6 Empirical for	3.1.1.6 Empirical formula						
30								
31	Provided by the Ap	Provided by the Applicant						
32								
33	Core material:	Titanium dioxide						
34	Coating materials:							
35		Sodium myristoyl sarcosinate – C17H32NNaO3						
36		Dimethicone – C8H24O2Si3						
37								
38		<pre>From Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf</pre>						
39								
40	3.1.2 Physical for	m						
41								
42	Provided by the Ap	plicant						
43								
44	Manufacturing proc	cess description:						
45	The manufacturing pr	ocess involves several steps:						

- Mixing: the substrate (titanium dioxide) and the first surface treatment (sodium myristoyl sarcosinate) are placed in a tank and mixed for a given amount of time. pH and

- temperature are controlled at mixing. The second and third treatments,
 dimethicone and aluminium hydroxide, are added subsequently, with pH and
 temperature checked at the end of each mix.
 Pressing: the product in the tank is transferred into a filter press, and pressed until it
 - *Pressing:* the product in the tank is transferred into a filter press, and pressed until it reaches the correct parameters.
 - *Heating:* the material is transferred into drying trays and left until the oven cycle is completed. Hydrophobicity and LOD are checked to ensure the quality of the manufacturing process.
 - Packaging

The process is conducted under optimum conditions and controlled at each step to ensure the
adequacy with expected results, and the repeatability and stability of the end material. Any
deviation to the process or check results is reported and solved.

15 General appearance:

Eclipse 70 is presented as a white powder. The morphological observation by scanning electron microscopy (SEM) reveals the presence of particles with a needle-like morphology, as illustrated in **Figure 2**.

19

14


5


6

7

8

9





20 21 22

23

28 29

30

36

37 38 39

40

Figure 2: Electron microscopy of Eclipse 70

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

3.1.3 Molecular weight

Provided by the Applicant:

31 Core material: Titanium dioxide - 79.9 g/mol
32 Coating materials: Aluminium hydroxide -78.004 g/mol
33 Sodium myristoyl sarcosinate - 321.4 g/mol
34 Dimethicone - 236.53 g/mol

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

3.1.4 Purity, composition and substance codes

41 **Provided by the Applicant:**42

43 The composition / purity of Eclipse 70 is reported in **Table 1**.

Table 1. Typical composition of Eclipse 70 1

Components	% w/w	CAS No.	EINECS No.
Ultrafine titanium dioxide	70	-	-
Titanium dioxide	(80-90)	13463-67-7	236-675-5
Aluminium hydroxide	(10-20)	21645-51-2	244-492-7
Sodium myristoyl sarcosinate	14	30364-51-3	250-151-3
Dimethicone	10	63148-62-9	Not regulated
Aluminium hydroxide	6	21645-51-2	244-492-7

The SCCS has noted that the nanomaterial under current evaluation is composed of core TiO_2 nanoparticles that constitute 70% w/w of the material, which is surface coated sequentially

with aluminium hydroxide (up to 6% w/w), sodium myristoyl sarcosinate (up to 14% w/w),

and dimethicone (up to 10% w/w). This means that, in the final form, Eclipse 70 nanoparticles

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

2 3 4 5 6 7 8 9

3.1.5 Impurities / accompanying contaminants

are composed of up to 30% w/w of the coating materials.

16 **Provided by the Applicant:** 17

SCCS comment

18 The technical data sheet of Eclipse 70 reports that the material does not contain heavy metals 19 (e.g., Hg, Cd, Pb, As, or Sb) beyond generally accepted limits.

20 The sample has been mineralised in a solution containing 4.5 mL HNO₃, 1.5 mL HCl and 1 mL HF. During 2 hours at 100°C. It is noticed that the full mineralization has not been achieved. 21 Typical impurities of Eclipse 70, measured by inductively coupled plasma atomic emission 22 23 spectroscopy (ICP-AES), are shown in Table 2. 24

25 Table 2. Typical impurities of Eclipse 70

Element	Technique	Results (%)
Ag	ICP-AES	< 0.00025
AI	ICP-AES	3.82
As	ICP-AES	< 0.0025
В	ICP-AES	< 0.0010
Ba	ICP-AES	< 0.00025
Be	ICP-AES	< 0.0025
Bi	ICP-AES	< 0.00025
Ca	ICP-AES	0.0047
Cd	ICP-AES	< 0.00025
Со	ICP-AES	0.072
Cr	ICP-AES	< 0.0013
Cu	ICP-AES	< 0.025
Fe	ICP-AES	0.0042
K	ICP-AES	0.0016
Li	ICP-AES	< 0.00025
Mg	ICP-AES	0.00073
Mn	ICP-AES	< 0.00025
Мо	ICP-AES	< 0.00025

14

15

Na	ICP-AES	0.027
Ni	ICP-AES	< 0.00025
Р	ICP-AES	0.0089
Pb	ICP-AES	< 0.0025
S	ICP-AES	0.098
Sb	ICP-AES	0.012
Se	ICP-AES	< 0.0025
Si	ICP-AES	0.038
Sn	ICP-AES	< 0.050
Sr	ICP-AES	< 0.00025
Ti	ICP-AES	37.4
TI	ICP-AES	0.017
V	ICP-AES	0.0017
Zn	ICP-AES	< 0.050

Opinion on new coating for Titanium Dioxide (nano form)

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf and RAPPORT #A2302555 - MIYOSHI EUROPE.pdf

3.1.6 Solubility

Provided by the Applicant:

Titanium dioxide is insoluble in water and organic solvents. It also has a very low dissociation constant in water and aqueous systems, and thus can be considered insoluble, also under physiological conditions (SCCS, 2014).

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

3.1.7 Partition coefficient (Log Pow)

Provided by the Applicant:

Not applicable for uncoated titanium dioxide.

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

5 SCCS comment

6 Whilst the SCCS agrees that measurement of octanol/water partition coefficient is not 7 applicable to uncoated titanium dioxide particles, Eclipse 70 has a surface coating composed 8 of inorganic/organic substances (resulting in a hydrophobic surface), which may affect 9 partitioning between hydrophilic/lipophilic phases. The OECD TG 126 may be followed in this 0 regard to provide hydrophobicity index of Eclipse 70.

3.1.8 Additional physical and chemical specifications

Provided by the Applicant:

38Crystallinity:Rutile titanium dioxide39Mean aspect ratio:2.8140Surface specific area: $15.14 \text{ m}^2/\text{g}$ 41Density: $2.2045 \pm 0.0009 \text{ g/cm}^3$ (measurement by Helium pycnometry)42VSSA^(*): $33.38 \text{ cm}^2/\text{cm}^3$

Zeta potential: 6.109 mV UV-Vis spectroscopy: Two absorption peaks are observable. One peak at 210 nm (Absorption = 0.7691), one peak at 357 nm (Absorption = 0.6355).

(*): Volume Specific Surface Area

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

10 SCCS comment

1 2

3

4

5 6

7 8

9

11 12

13

14

15

16 17 18

19

22

23

24 25

27 28

29 30 The SCCS has noted that the Specific Surface Area of the materials tested for skin penetration (789455-Miyoshi_Eclipse-Microscopy_Final_26Apr23.pdf, page 29/37) is 5.8 times higher than the one reported above (87.6 m^2/q versus 15.14 m^2/q). The Applicant needs to confirm which value is correct, or whether they reflect variation between the two different batches of the material.

3.1.9 **Particle size**

20 **Provided by the Applicant:** 21

Particle/aggregate size distribution analysis of Eclipse 70 was first performed using laser diffraction (LD) which produces distributions weighted according to the intensity of light scattered by each size of particle/aggregate. The D10 range is reported as $1.42-1.45 \ \mu m$, while the D90 is reported as 5.02- 5.73 µm. This represents a mean size ranging between 26 3.14 to 3.47 μ m. Details are provided in the following Figures.

Laser Scattering Particle Size Distribution Analyzer Partica LA-960 Laser Scattering Particle Size Distribution Analyzer Partica LA-960 HORIBA LA960 for windows [Wet] Ver2.20 HORIBA LA960 for windows [Wet] Ver2.2
 Sample name
 : ECLIPSE70-D13-NT-77891

 Material
 : TITANIUM (rutile)

 Source
 : OVEN# 18
 Lot number : 6A0209Z70 Data name : 6A0209Z70 Sample name : ECLIPSE70-D13-NT-77891 Material : TiO2 rutile Lot number : 8K0118Y24 Data name : 8K0118Y24 Source Circulation speed ion speed ion speed initiance (R) : ince (B) ince (R) Circulation speed 8 00:10 (1) 8 03:00 (2) Agitation speed 1 94.5 (%) 89.8 (%) TiO2-Ruti [titanium 15 7 99.9 (%) 98.5 (%) TiO2-Rutile [titanium oxide(rutile)(2.750 - 0.000i),isopro 15 oxide(rutile)(2.750 - 0.000i),isopro 3.28079 (µm) 3.46766 (µm) 3.6547 (µm) 2.99980 (µm Median size Mean size Mode size Span Diameter or 2.99900 (µm) 3.14467 (µm) 3.2012 (µm) 1.1891 (%)- 0.9557 (μm) (%)- 2.1104 (μm) (%)- 2.9998 (μm) (%)- 4.0079 (μm) 0.7468 (µm) 2.2328 (µm) 3.2808 (µm) 4.4740 (µm) 7.2217 (µm) D10 : 1.45121 (µm) D90 : 5.01831 (µm) D10 : 1.41598 (µm) D90 : 5.73094 (µm) 12 12 10 10 (%) 8 -50 -20 10 Diameter (um) Diameter (µm) Figure 3a: Laser scattering particle size Figure 3b: Laser scattering particle size distribution (From Ref.: Annex 1 Laser distribution (From Ref.: Annex 1 Laser scattering particle size distribution-PSDscattering particle size distribution-PSD-6A0209Z70.pdf) 8K0118Y24.pdf)

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

31

32 **Table 3:** Laser scattering size distribution (number based): D10, D50, D90 and Dmean for two batches (data extracted by the SCCS from Annex 1_Laser scattering particle size 33

distribution-PSD-6A0209Z70.pdf and Annex 1_Laser scattering particle size distribution-PSD-34

35 8K0118Y24.pdf)

Materials ECLIPSE70-D13- NT-77891	D10 (μm)	D50 (μm)	D90 (μm)	Dmean (µm)
Lot 6A0209Z70	1.45121	2.99980	5.01831	3.14467
Lot 8K0118Y24	1.41598	3.28079	1.41598	3.46766

8 9 10

2

SCCS comment

The SCCS considers that the use of methods based on laser diffraction is only appropriate for larger sized agglomerates/aggregate, and not for particle size measurement of constituent particles in the nano scale.

3.1.10 Microscopy

12 **3.1.10.1** Morphological observation of particles by SEM

13

11


14 From Applicants:

15 16

16 SEM observations reveal the presence of particles with a needle – like morphology. Some of

17 these particles appear to have nanometric dimensions (< 100 nm).

18



19 20

Figure 4: SEM observations (secondary electron mode) of sample 2303-E01 32 782 (from Annex 1_Material characterisation report_PC_RAPPORT #A2302555 - MIYOSHI EUROPE en-US.pdf and RAPPORT #A2302555 - MIYOSHI EUROPE.pdf)

24

The elemental analysis by EDX carried out on the sample reveals that these particles are mainly composed of Carbon (C), Oxygen (O) and Titanium (Ti), a minority of Aluminium (Al), as well as traces of Sulfur (S).

28 It should be noted that the Silicon (Si) detected in EDC probably comes from the Silicon Wafer

29 used as a support for analysis.




Figure 5: SEM – EDX analysis of Sample 2303-E01 32 782 (from Appendix - RAPPORT

2 3 4 5 6 7

8 SCCS comment

#A2302555 - MIYOSHI EUROPE.pdf)

Only a single sentence is provided in the submission to describe how samples were prepared
prior to measurement of particle size distribution: "A dispersion of the sample is made in a
10 mL volume of Isopropanol. 2.5 µL of this solution is then deposited in a Silicon Wafer using
a Spin Coating technique".

Despite the SCCS request for further information, no more details were provided by the Applicant on the sample preparation method used. The SCCS considers the provided information as inadequate because appropriate sample preparation to achieve adequate dispersion of nanoparticles is crucial for physicochemical characterisation and toxicological testing of nanomaterials (SCCS Guidance on Nanomaterials: SCCS/1655/23).

19

20 **3.1.10.2** Primary particle size distribution

2122 Provided by the Applicant:

The primary particle size distribution of Eclipse 70 (raw powder) was analysed by scanning
electron microscopy (SEM), showing a monomodal distribution with a peak centred at about
20 nm (Figure 7).

27 28 Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

A count of 305 particles was performed using an image analyzer. The minimum Feret diameter was chosen as the dimensional parameter. This dimension was preferred because in the definition, the term "one or more dimensions" is mentioned. The counted particles were chosen randomly on the Wafer. Only particles with a discriminable physical countour were counted. The size of the primary particles has priority over the agglomerates or aggregates, since the latter will be considered as nanomaterials if the particles that compose them are nanometric.

36

A selection of SEM images, with and without the counting performed, is presented in thefollowing Figures.

Opinion on new coating for Titanium Dioxide (nano form)





Figure 6: SEM micrographs of Sample 2303-E01 32 782 (from Appendix - RAPPORT #A2302555 - MIYOSHI EUROPE)



Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf and RAPPORT #A2302555 - MIYOSHI EUROPE.pdf




Figure 7: Particle size distribution of Eclipse 70 measured by SEM (sample 2303-E0132782)



11

12

13 14

15 The particle size distribution of the sample is monomodal with a peak centered at about 20 16 nm. The particle size ranges from 12 to 56 nm. 17

18 The results of the particle size distribution (% cumulative) show that more than 50% of the 19 particles in the numerical size distribution have a size less than 100 nm. Overall, average 20 particle size was reported as 22.4 nm, d10 as 16.3 nm and d90 as 30.0 nm.

2122 The results are listed in the Table below.

Table 4: Size distribution determined by SEM (average value, D10%, D50%, %nanoparticles, aspect ratio)

Sample Reference	Average Value (nm)	Value at 10% cumulative (nm)	Median Value* (nm) (50% cumulative, according to 2022/C 229/01)	% of nanoparticle s in the sample of particles analyzed*	Aspect Ratio
2303- E0132782 <i>ECLIPSE70-</i> <i>D13-NT-77891</i>	22.4	16.3	20.9	100	2.81

9

Ref.: Annex 1_Material characterisation report_PC_RAPPORT #A2302555 - MIYOSHI EUROPE en-US.pdf and RAPPORT #A2302555 - MIYOSHI EUROPE.pdf

10 SCCS comment

Figure 7 shows particle size distribution of Eclipse 70 measured by SEM (sample 2303-E0132782). However, it is not clear how the line was drawn and whether it is based on a mathematical model. It is notable from the Figure that the particle size distribution is not completely monomodal.

15

Also, aspect ratio of the nanoparticles is given but no explanation is provided on how the aspect ratio was determined. In the absence of information on full aspect ratio distribution based on individual particle size measurements, it is not clear if the given aspect ratio is a median/mean value.

20 21

22 Provided by the Applicant:

23

Summary of the Particle size of Eclipse 70 based on Laser scattering and SEM analyses:

26

28

27 **Table 5.** Particle size of Eclipse 70

Material Particle size distribution Code							
	Laser sca	Laser scattering analyser (um)			Number weighted median based on SEM (nm)		
	D10	D90	Mean size	D10	D90	Mean size	
Eclipse 70	1.42 - 1.45	5.02 - 5.73	3.14 - 3.47	16.3	30.0	22.4	

29 30

31

32

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

33 SCCS comment

Despite the uncertainty due to the lack of details on particle dispersion, the information provided on particle size distribution measured by electron microscopy shows that median particle size of Eclipse 70 is around 21 nm. Since up to 30% (w/w) of the material is comprised of coating substances, the actual median size of core TiO₂ nanoparticle is most likely below 21 nm. This renders Eclipse 70 outside the particle size range covered in the SCCS Opinion (SCCS/1516/13 - Revision of 22 April 2014): "....have a median particle size based on number size distribution of 30 to 100 nm (measured
by different methods) as submitted in the dossier, or larger. Thus, whilst primary particle size
may be smaller (around 10 nm), the median particle size of TiO₂ nanomaterials in a cosmetic
formulation must not be smaller than 30 nm in terms of number-based size distribution".

In response to the SCCS request for further information, the Applicant provided the following
explanation:

While the coating represents a significant proportion by weight, the overall thickness of the coating layer is only a few nanometers. We have analysed the particle size of both untreated and treated particles (using the same method, SEM by number, and the same lot) and have found a very comparable D50 (median particle size). The difference in particle size between the untreated and treated particles is

14 not significant, indicating that the coating does not significantly affect the overall PSD."


In the absence of any supporting data, the SCCS regards the Applicant's narrative statement
as unsatisfactory, and maintains the view that the median particle size range of Eclipse 70 is
most likely outside that covered in the previous SCCS Opinion (SCCS/1516/13 - Revision of
22 April 2014).

20 21

22 3.1.11 Crystal structure

24 **Provided by the Applicant:**

25



- 26
 27 Figure 8: X ray diffraction pattern provided by Applicant (from Ref. RAPPORT #A2302555
 28 MIYOSHI EUROPE.pdf)
 29
- 30 The crystal phases identified for this sample are as follows:
- 31
- 32 33
- 34
- 35
- 36
- 37 38

Table 6

2	
/	
_	

Reference Sample / Référence Echantillon	Identified crystal phases / Phases cristallines identifiées	ICDD sheet / Fiche ICDD
2303-E0132782 ECLIPSE70-D13-NT-	Rutile TiO ₂ / TiO ₂ rutile	01-089-0552
77891		

Ref.: Annex 1_Material characterisation report_PC_RAPPORT #A2302555 - MIYOSHI EUROPE en-US.pdf and RAPPORT

#A2302555 - MIYOSHI EUROPE.pdf

9 SCCS comment10 The SCCS has noted

The SCCS has noted that some minor XRD peaks have not been identified in the data provided in the submission.

3.1.12 UV absorption

16 Provided by the Applicant:17

18 Two absorption peaks are observable. One at 210 nm (Abs.) 0.7691) and one at 357 nm (Abs. = 0.6355).




Table 7: Absorption UV – visible peaks

Absorption peak (nm)	Absorption
210	0.7691
357	0.6355

From Ref.: Annex 1_Material characteri	sation
report_PC_RAPPORT #A2302555 - MIYOSHI EUROPE en-l	
and RAPPORT #A2302555 - MIYOSHI EURO	PE.pdf

3.1.13 Surface characteristics

SCCS comment

No specific information is provided about the surface characteristics of Eclipse 70. However, from the information provided on coating materials, it can be anticipated that the surface characteristics of fully coated Eclipse 70 would be determined by the outermost layer of dimethicone (i.e. the coated nanoparticles will be hydrophobic).

3.1.14 Droplet size in formulations

2

/

3.1.15 Homogeneity and stability

Provided by the Applicant:

Based on stability information reported in the confidential **Annex I**, it is concluded that an optimum manufacturing process is needed to develop strong hydrophobic surfaces, and stable surface treatment.

The manufacturing process described above (see 'Physical form' paragraph) respects Good Manufacturing Practices and is strictly controlled for any deviation. Should any modification occur, its potential consequences are investigated, reported, and resolved. The end-product must respect the same Quality Control parameters to be released (hydrophobicity and proportion of treatment).

Stability testing is performed under strictly defined conditions, allowing the shelf life to be set at 3 years.

Different samples are taken during the manufacturing process to ensure the homogeneity of treatment within the batch.

33 34 35

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

36 SCCS comment

The Applicant provided data from a test to indicate stability of the coating. The purpose of the test was described as to confirm ECLIPSE 70 surface treatment stability with comparing incorrect surface treatment process sample. The reported method involved, dispersing, filtering, making a 'press-cake' and dropping 1-2 water droplet on press-cake, and monitoring contact angle at 0 sec, 20 sec, 60 sec, 15 min, 30 min and 45 min.

- In response to the SCCS request for further information, the Applicant provided the followingexplanation:
- 45

46 "The water droplet contact angle test is used to confirm the stability of the surface treatment, 47 even after applying an isopropanol (IPA) washing process, which is rougher than normal 48 condition of use. This test indicates that our product, with our specific process, maintains a 49 high contact angle, which signifies that the pigment retains its water resistance effect even 50 after the IPA washing process. To further prove the stability of the coating over time, we have 51 conducted hydrophobicity tests over a longer period, specifically up to 48 months (see results 52 in annex II of this document). These results demonstrate that the coated TiO₂ remains stable 53 and retains its water resistance properties even after an extended period, providing additional 54 evidence of the coating's stability during the shelf-life of the product."

55

56 The Applicant also provided a Table (Table 8) to indicate stability of the coating in terms of 57 maintenance of hydrophobicity over 48 months (Float test, and Stir test).

Opinion on new coating for Titanium Dioxide (nano form)

Table 8

Test	Method	Specification	0 Month (2-15-2018)	2 Month (4-15-2018)	3 Month (5-15-2018)	6 Month (8-15-2018)	12 Months (2-15-2019)	24 Months (2-15-2020)	36 Months (2-15-2021)	48 Months (2-15-2022)
Appearance, Color, Odor and Feel	Q-C001	Matches Std	Matches Std	Matches Std	Matches Std	Matches St <mark>d</mark>	Matches Std	Matches Std	Matches Std	Matches std.
Loss on Drying	Q-C015	Less than 2.0%	0.60%	1.0%	1.2%	1.2%	1.7%	1.88%	1.59%	1.19%
Float Test (Hydrophobicity)	Q-C014	Floats on still water for more than 1 hour	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass
Stir Test (Hydrophobicity)	Q-C028	≥5.0/≥5.0/≥5.0	5.0/5.0/5.0	5.0/5 <mark>.</mark> 0/5.0	5.0/5.0/5.0	5.0/5.0/5.0	5.0/5.0/5.0	5.0/5.0/5.0	5.0/5.0/5.0	5.0/5.0/5.0
TiO2 Content	Q-E018	55.0 - 6 5.0 %	58.7%	61.17%	60.70%	61.34%	60.53%	60.78%	61.16%	60.57%
Microbial Content	Q-D002	Less than 100 cfu/gm, No gram negative	Pass	Pass	Pass	Pass	Pass	Pass	Pass	Pass

3

The SCCS regards the provided information unsatisfactory because validity and relevance of the used method have not been established in terms of how the measurement of a change in the water contact angle (over short intervals, and an overall short period of time) could be considered to depict long term stability of the coating on the nanomaterial. Similarly, details have not been provided on the 'Float' and 'Stir' methods to enable assessment of their validity and relevance to demonstrate stability of the coating.

3.1.16 Other parameters of characterisation

Provided by the Applicant:

10		
16	Melting point:	Not provided
17	Boiling point:	Not applicable
18	Flash point:	Not applicable
19	Vapour pressure:	Not applicable
20	Density:	Not provided
21	Viscosity:	Not provided
22	рКа:	Not provided
23	Refractive index:	Not provided
24		
25		
26		

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

Ref.: Table 2, 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

3.1.17 Summary on supplementary physicochemical characterisation

Provided by the Applicant:

Table 9. Additional parameters for the identification and characterisation of Eclipse 70

Material code	Crystal size (nm) (XRD)	Aspect ratio (L/W)	UV absorption (extinction coefficient)	Zeta potential (mV)	Photo- catalytic activity (%)	Photo- stability	Coating stability
Eclipse 70	N/A	2.81	210 nm and 357 nm	6.109	0.74	N/A	Stable

1 SCCS comment

2 The SCCS is of the view that where evidence is provided to show that photocatalytic activity 3 remained guenched over a long period of time, it could be considered an indirect way of 4 ascertaining stability of a coating on a photoreactive/photocatalytic nanomaterial. In this 5 regard, the Applicant provided data on photocatalytic activity (Table-9) to indicate that it is 6 below the acceptable level of 10%, compared to the same material without surface coating. 7 However, the provided evidence only comprised of plate images without any detail on how 8 photocatalytic activity was measured, calculated, or what it was compared with to conclude 9 that it was within the acceptable limit.

10

In response to the SCCS request for further information, the Applicant provided the following 11 12 explanation: "The method outlined in SCCS/1516/13 was followed for testing. The 13 photocatalytic activity was measured on the coated test sample and the non-coated control. The activity of the test sample was compared with that of the control. The measured activity 14 values for the test and control samples were 39.49 and 0.29, respectively. The final calculated 15 16 activity was 0.74% (0.29/39.49=0.74%). As per the SCCS NoG (2023), the activity of the coated material should not be more than 10% compared to the non-coated control to be 17 18 considered acceptable. In our case, the calculated activity of 0.74% falls well below this limit, 19 indicating that the photocatalytic activity of the coated material remains quenched."

20

In the absence of detailed information, the SCCS regards the Applicant's narrative statement as unsatisfactory and reiterate that full experimental details of the test should be provided to enable evaluation of the validity of the results.

24 25 26

27

3.2 TOXICOKINETICS

28 **Provided by the Applicant:**

29 30 Eclipse 70 is reported to have a stable coating during long-term storage, hence no release of 31 individual coating materials is expected under the proposed use conditions. From the 32 toxicological evaluation point of view, the core and coating materials were considered as one 33 entity.

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

34 35

36

37 SCCS comment

The SCCS regards the Applicant's narrative statement as unsatisfactory and considers that stability of the composite coating has not been demonstrated either directly (see 3.1.15) or indirectly (see 3.1.17).

41 42 43

44

45

3.2.1 Dermal / percutaneous absorption

An OECD Test Guideline 428 compliant in vitro percutaneous absorption study has been
provided in the submission. The study was conducted with a representative cosmetic
formulation containing 10% w/w of Eclipse70.

50 In vitro percutaneous absorption (human skin)51

52	Guideline:	OECD TG 428			
53	Test system:	Human skin (Split-thickness)			
54	Test substance:	10% (w/w) amino acid treated nano-titanium dioxide			
55		with dimethicone (ECLIPSE70-D13-NT-77891,			
56		abbreviated Eclipse 70) in a representative sunscreen			
57		formulation (A69-14-36A-MOD)			

1	Formulation batch:	92-114
2	TiO_2 content in the formulation:	6.07% (w/w)
3	Conversion factor:	2.76 (to convert from titanium to Eclipse 70)
4	Route:	Topical application
5	Application technique:	Static diffusion
6	Thickness of skin:	350-400 μm
7	Duration:	24 hours
8	Washing of test formulation:	Yes
9	Dose of test formulation:	5 mg/cm ²
10	Applied mass:	529 µg/cm ²
11	Surface area of exposed skin:	0.64 cm ²
12	Number of samples:	12
13	No of donors:	4
14	No of cells per donor:	3
15	Membrane integrity:	Yes
16	Receptor fluid:	Physiological saline
17	Sampling:	0.5, 1, 2, 4, 8 and 24 hours
18	Analytical method:	Inductively coupled plasma mass spectrometry (ICP-
19		MS)
20	Exposure time:	24 hours
21	GLP:	Yes
22	Study period:	2022-23

23 24 **Method:**

25 The *in vitro* absorption of Eclipse 70 in a representative sunscreen formulation at 10% was 26 investigated in a GLP-compliant study conducted according to OECD Test Guideline 428. 27 Healthy split-thickness human skin membranes (350-400 µm) with an exposure area of 0.64 cm2 were mounted into static diffusion cells with receptor fluid present in the receptor 28 29 chamber. A skin surface temperature of 32 ± 1 C was maintained throughout the experiment. 30 An initial electrical resistance barrier integrity assessment was performed for all skin samples, and skin samples exhibiting a resistance greater than 7.7 k Ω were accepted in the study. The 31 32 test formulation was applied at a dose of 5 mg/cm2 to twelve skin membranes from four 33 different donors. The cells were open to the atmosphere. An analytical method capable of 34 detecting the presence of elemental titanium by Inductively Coupled Plasma-Mass 35 Spectrometry (ICP-MS) was developed for all relevant samples (i.e., mock doses, receptor 36 fluid, skin wash, tissue swabs, tape strips, donor wash, receptor wash, epidermis, and 37 dermis). The skin membranes were dosed with test formulation, a non-dosed control group 38 served to determine the background levels of titanium in the test system. The percutaneous 39 absorption was assessed by collecting receptor fluid samples at 0.5, 1-, 2-, 4-, and 8-hours 40 post-dosing. At 24 hours post-dosing, the exposure was terminated by washing the skin 41 surface with a commercial hand wash soap concentrate, followed by rinsing with a dilute soap 42 solution (2%, v/v) and drying of the surface with tissue swabs. The 24-hour receptor fluid 43 was collected from the receptor chamber and retained for analysis. The skin was removed 44 from the static cells, the stratum corneum tape-stripped, and the skin was divided into 45 exposed and unexposed skin sections. The exposed skin was separated by scraping the 46 epidermis from the dermis using a scalpel. The receptor chambers were rinsed with 2% nitric 47 acid, which was retained for subsequent analysis.

48

All samples taken were analysed for titanium by inductively coupled plasma mass spectrometry (ICP-MS) using a method validated by the contract laboratory. The titanium levels in the tissue samples and the tape strips were provided as elemental titanium per sample. The titanium content in the receptor fluid, donor and receptor chamber wash was provided as concentration (ng Ti/mL). To convert the levels of elemental titanium to that of Eclipse 70, a conversion factor of 2.75 was applied.

- 55 56
- 57

1 Results:

2 The ICP-MS analysis revealed that most of the epidermis, dermis, receptor fluid and receptor 3 wash values were below the method's limit of quantification (LOO), similar to what was observed in the blank control group. The initial development and validation of the method 4 5 was complex due to titanium being a challenging and ubiguitous analyte, which is present in 6 nature in higher amounts than most trace elements. Only in single test samples (e.g., cell 7 7 at the 0.5-hour measurement), the measured value slightly exceeded the LOQ of 10 ng/mL. 8 Overall, the absorption profiles looked similar for all test samples with absorption of Eclipse 9 70 being below the LOQ throughout the experimental period. The same was observed in the 10 blank control group. Hence, it should be noted that the actual concentration of titanium values provided below in Tables 7 and 8 [of the submission], will be between zero (best case, lower 11 bound) and the LOQ value (worst case, upper bound). Although the pre-dose values showed 12 13 titanium contents greater than the LOQ, the pre-dose values were set at 0.00 ng/mL as the 14 formulation had not been introduced at that time point. Where the measured values were 15 below the LOQ, the LOQ value was applied as worst case to all calculations. The mass balance 16 for all individual samples was within $100 \pm 15\%$ except for six cells (i.e., cells 2, 3, 4, 5, 7, 9 17 which revealed a mass balance >115%). The mean mass balance was 113.33% of the applied 18 dose at 24 hours post-dose. The high mass balance was a result of almost all samples being 19 below the LOQ. None of the cells were rejected, and the results were provided as mean values 20 (n = 12).21

22 Table 10 presents the mean absorption results and distribution at 24 hours post dose 23 obtained for the Eclipse test sunscreen formulation. Most of the applied dose was washed off 24 at 24 hours post application (i.e., 7.42 and 98.89% recovered in the skin wash and tissue 25 swabs, respectively). At 24 hours post dosing, a further 0.08% was recovered in the donor 26 chamber wash. The material recovered in the donor wash was almost certainly the material 27 that was dislodged from the skin during the washing procedure. Therefore, the total 28 dislodgeable dose was 106.40% of the applied dose. The mean total unabsorbed dose was 29 110.74% of the applied dose. This consisted of the dislodgeable dose, unexposed skin 30 (0.82%) and the Eclipse 70 associated with the *stratum corneum* (3.53%).

31

32 The amounts retained in the stratum corneum at 24 hours were not considered dermally 33 absorbed. With the worst-case assumption of absorption at the LOQ, the totally absorbed 34 dose, the sum of the receptor fluid (0.25%) and receptor chamber wash (0.08%), was 35 calculated to be 0.33%. With the same worst-case assumption, the epidermis and dermis 36 contained 1.44% and 0.82% of the applied dose, respectively. Due to epidermal removal during the tape stripping, the values from the stratum corneum for cells 5, 8, 10 and 11 37 (stratum corneum (SC) 11-15 and SC 16-20 values for cell 5, SC 6-10 and SC 11-15 values 38 39 for cell 11, SC 6-10 value for cell 10 and SC 16-20 value for cell 8) were added to the 40 epidermis, resulting in the values for epidermis above the LOO of 0.82%. Considering the upper bound levels (measurements below the LOO was considered as equal to the LOO), the 41 42 dermal delivery, the sum of absorbed dose and exposed skin (epidermis and dermis), was 43 calculated to be 2.58%. Since most receptor fluid values were below the LOQ, it was not 44 possible to determine the extent of absorption. To present the most conservative risk 45 assessment value, the potentially absorbable dose value has been calculated and reported in 46 the study report. However, it should be pointed out that this value is "worst-case".

47

Table 10. *In vitro* percutaneous absorption of Eclipse 70 through human skin in terms of %
applied dose and amount per skin unit area (upper bound levels)

Opinion on new coating for Titanium Dioxide (nano form)

	ECLIPSE 70				
Test Formulation	Eclipse Test Sunscreen				
Concentration of Test Item (w/w)		109	%		
Applied Mass (µg/cm²)		52	9		
Number of Samples		12	2		
Distribution	% App	olied dose	ł	ıg/cm²	
Distribution	Mean	SD	Mean	SD	
Donor chamber wash	0.08	0.02	0.433	0.129	
Dislodgeable Dose	106.40	7.76	562	41.0	
Stratum corneum	3.53	1.01	18.7	5.35	
Unexposed Skin	0.82	0.00	4.31	0.00	
Total unabsorbed dose	110.74	8.05	585	42.6	
Epidermis	1.44 [@]	0.83	7.62 [@]	4.41	
Dermis	0.82 ^{\$}	0.00	4.31 ^{\$}	0.00	
Receptor Fluid (RF)	0.25 ^{\$}	0.00	1.30 ^{\$}	0.00622	
Receptor Wash (RW)	0.08 ^{\$}	0.00	0.431 ^{\$}	0.00	
Total Absorbed Dose (RF+RW)	0.33	0.00	1.73	0.00622	
Dermal Delivery	2.58	0.83	13.7	4.41	
Potentially absorbable dose	5.25	0.80	27.7	4.24	
Mass balance	113.33	8.09	599	42.7	

\$ Below limit of quantification.

1 2 3 @ Above the limit of quantification (LOQ) for 4 cells out of 12. The values for the 8 cells were below LOQ of 0.82%

Dislodgeable dose = skin wash 24 hours + tissue swab 24 hours + donor chamber wash.

4 5 6 7 Stratum corneum = tape strips 1 to 20.

Total unabsorbed dose = dislodgeable dose + *stratum corneum* + unexposed skin.

8 Total absorbed dose = cumulative receptor fluid + receptor chamber wash.

9 Dermal delivery = absorbed dose + epidermis + dermis.

- 10 Potentially absorbable dose = dermal delivery + stratum corneum 3-20.
- 11 Mass balance = unabsorbed dose + dermal delivery.

The distribution of Eclipse 70, by mass, at 24 hours post dose as shown in **Table 10** reflects 12 13 the upper bound levels while measurements below the LOQ were considered as equal to the LOQ. The mass balance, total dislodgeable dose, unabsorbed dose, absorbed dose and dermal 14 15 delivery were 599, 562, 585, 1.73 and 13.7 µg/cm2, respectively.

16 17

18 Of the 12 cells dosed with Eclipse test sunscreen, 4 cells (i.e., cells 5/8/10/11) had the epidermis removed during the tape stripping procedures. Although representative stratum 19 20 corneum values have been added to the epidermis values for these cells as a "worst-case" 21 scenario, there is a possibility that these stratum corneum values did not contain any levels of active ingredient even with epidermis removed. In addition to the skin samples dosed with 22 23 the test sunscreen, a blank control group was tested. This group was included to ascertain 24 the intrinsic levels of background titanium associated with the test system and to enable the 25 correction of the Eclipse test sunscreen data to account for this, if appropriate. Although the 26 donor wash and tissue swabs displayed slightly increased titanium content, the amount was 27 deemed small enough to be negligible. Therefore, data adjustment was not considered to be 28 required. 29

30 Conclusion

In the dermal absorption study conducted by Kravcenko (2023a), no absorption of Eclipse 70 31 above the limit of quantification was observed. Hence, the actual concentration would be 32 between zero (best case; lower bound) and the LOQ value (worst case; upper bound). The 33

absorption profiles looked similar for tested samples including the blank controls. Most of the 34

applied dose (106.4%) was removed at 24 hours post dosing by washing the skin samples, 35

indicating that the applied Eclipse 70 was present in the dislodgeable dose. The mean total recovery of 113.3% was within the SCCS acceptance criteria of 85-115%.

(Kravcenko, 2023a)

6 **B. Identification of Eclipse 70 in human skin following** *in vitro* percutaneous 7 **absorption by Transmission Electron Microscopy (TEM)**

8 In addition to afore mentioned study, a separate study investigating the presence of Eclipse 9 70 (titanium) in human skin by electron microscopy following topical application of Eclipse 70 present at 10% (in a representative sunscreen formulation (A69-14-36A-MOD)) to human 10 skin membranes was conducted. For this purpose, the Eclipse 70 containing sunscreen 11 12 formulation was applied to the mounted human split-thickness skin membranes at a rate of 13 5 mg/cm2 (3.2 mg). The skin membranes were mounted in static diffusion cells. The cells 14 were positioned in a manifold heated to maintain a skin surface temperature of $32^{\circ}C \pm 1^{\circ}C$ and the receptor fluid volume made up to the pre-calibrated line. The receptor fluid was mixed 15 16 using a magnetic stirrer flea which was placed in the receptor chamber. An electrical resistance barrier integrity assessment was performed and any skin sample exhibiting 17 18 resistance lower than 7.7 k Ω was excluded from subsequent absorption measurements. 19

20 A positive displacement pipette was used to apply the formulation evenly over the surface of the skin membranes. Two control samples of human skin membranes were treated in the 21 22 same manner but left un-dosed. The cells were dismantled, and the skin under the cell flange 23 (unexposed skin site) was cut off from the exposed skin site. Only the exposed skin was 24 retained for analysis. The 24-hour post-dose exposed skin samples were cut in half. Each skin 25 piece was individually fixed using Modified Karnovsky's Fixative. The samples were sent in 26 cold packs for further processing and sectioning before TEM analysis. Samples were processed 27 for TEM through 0.1M phosphate buffer rinses, post-fixed in 1% osmium tetroxide in 0.1M 28 phosphate buffer, rinsed in distilled water, dehydrated through a graded ethanol series (50, 29 70, 95, and 100% ethanol), transitioned through propylene oxide, infiltrated with Epon-30 Araldite resin (1:1 resin-propylene oxide, 3:1 resin propylene oxide, pure resin), and 31 embedded in pure Epon-Araldite resin. The blocks were thick sectioned at approximately 0.5 32 microns, with sections mounted on glass slides and stained with 1% Toluidine blue. Selected 33 blocks were trimmed to allow thin sectioning at approximately 70-90 nm, with the sections mounted on copper grids. The grids were examined on a JEOL JEM-1400+ transmission 34 35 electron microscope (TEM) without post-staining to avoid obscuring the heavy metal test 36 substance. The examination included reviewing the full length of the epidermis and adjacent dermis visible on each grid, with special attention to any electron-dense features in size range 37 38 of approximately 10-200 nm.

3940 **Results**

1

2

3 4

5

All examined skin samples revealed recognisable features of stratum corneum, epidermal-41 42 dermal border and upper dermal tissue. Examination of control samples included 43 representative images of any electrondense features, which primarily consisted of cytoplasmic 44 bodies, which could be consistent with melanosomes, especially near the epidermal-dermal 45 border. Some of these bodies were also present in the cytoplasm of the outer corneocytes. 46 Small amounts of amorphous material, possibly degraded desmosomes or lipids could also be 47 seen between and along the outermost corneocytes and was of similar electron density to the 48 melanosome-like bodies.

49

Examination of most of the dosed samples (cell 2, 5 and 6) revealed very strongly electrondense material but only along the outer *stratum corneum*. The material was darker than the melanosome-like bodies and degraded desmosomes. At higher magnifications the material was seen to be made up of particles of regular size and shape, consistent with images of the test item. Cell 4 had very little of the electron-dense material present, with just a few particles evident along outer corneocytes.

1 Conclusion

The electron microscopy images obtained in this study demonstrated that the titanium dioxide present in the Eclipse sunscreen formulation remained on the surface of the skin along the outer *stratum corneum* (SC). No titanium could be visualised in the inner layer of the SC or in the epidermis or dermis.

(Kravcenko, 2023b)

8 Overall conclusions of the Applicant on dermal absorption of Eclipse 70

9 In line with previously conducted dermal absorption studies with coated and uncoated 10 titanium dioxide (nano form), the study conducted with a representative sunscreen 11 formulation containing 10% Eclipse 70 did not provide any evidence for dermal absorption. 12 For almost all samples, the titanium levels measured by ICP MS in epidermis, dermis, receptor 13 fluid and receptor wash were below the methods limit of quantification (LOQ) and not different 14 to the blank controls.

16 This finding was confirmed by an additional study conducted by the applicant, who 17 investigated in a similar test set-up and dermal absorption experiment the presence of Eclipse 18 70 applied topically to skin a sunscreen formation in the skin by TEM. This study demonstrated 19 that all titanium dioxide (Eclipse 70) applied to the skin membranes remained on the surface 20 of the skin along the outer *stratum corneum*. As it was not possible to accurately quantify the concentrations and knowing that the actual concentrations of titanium in the different skin 21 22 samples are between zero (best case, lower bound) and the LOO (worst case, upper bound), 23 the study report presents the study results by considering lower bound (zero) and upper 24 bound (LOQ) levels (see Table 11).

25

6

7

- 26
- 27
- 28

29

30 31

- Table 11: Absorption values obtained through human split-thickness skin, considering lower 1 2
 - bound (zero) and upper bound (LOQ) levels.

1)	
	۱.	
		2

Test substance	Amino acid treated nano-titanium dioxide with dimethicone (Eclipse 70) (lower bound - LOQ values reported as zero / best-case scenario)	Amino acid treated nano-titanium dioxide with dimethicone (eclipse 70) (upper bound - LOQ values / worst-case scenario)	
Test Formulation	Eclipse Tes	t Sunscreen	
Concentration of Test Item (w/w)	10% (corresponding to 6.0	5% titanium dioxide (w/w))	
Applied Mass (µg/cm²)	5:	29	
Number of Samples	2		
Distribution	% Applied Dose)		
Donor Chamber Wash	0.06 %	0.08 %	
Dislodgeable Dose	106.38 %	106.40 %	
Stratum corneum	0.27 %	3.53 %	
Unexposed Skin	0.00 %	0.82 %	
Total Unabsorbed Dose	106.64 %	110.74 %	
Epidermis	0.35 %	1.44 %	
Dermis	0.00 %	0.82 %	
Total Absorbed Dose	0.00 %	0.33 %	
Dermal Delivery	0.36 %	2.58 %	
Potentially Absorbable Dose	0.44 %	5.25 %	
Mass Balance	107.00 %	113.33 %	

Dislodgeable dose = skin wash 24 h + tissue swab 24 h + donor chamber wash.

Stratum corneum = tape strips 1 to 20.

45 67 8 Total unabsorbed dose = dislodgeable dose + *stratum corneum* + unexposed skin.

Total absorbed dose = cumulative receptor fluid + receptor chamber wash.

9 Dermal delivery = absorbed dose + epidermis + dermis.

10 Potentially absorbable dose = dermal delivery + *stratum corneum* 3-20.

11 Mass balance = unabsorbed dose + dermal delivery.

12 13

14 The results indicate that most of the applied dose (106.4%) was removed at 24 hours post 15 dose by washing the skin samples, suggesting that the applied Eclipse 70 (TiO₂) was entirely present in the dislodgeable dose. Since most of the percent absorption values were below the 16 17 LOQ, it was not possible to accurately determine the extent of absorption. Hence, considering lower (LOQ values reported as zero) and upper bound (LOQ values) absorption levels through 18 19 skin, the theoretical worst case dermal delivery was 0.36 and 2.58%, respectively. The dermal 20 delivery reflects the sum of the epidermis, dermis and receptor fluid and wash. The mass 21 balance was 107.00 and 113.33%, respectively.

22

23 In summary, following the topical application of a sunscreen formulation containing 10% 24 Eclipse 70, no absorption through the human skin of the test substance was observed beyond 25 the most upper layers of the stratum corneum. The absorption measured throughout the experiment was below the LOQ for all layers. The mean total recovery (i.e., 107-113% 26 27 considering the lower or upper bound) was within the SCCS acceptance criteria of 85-115%. 28

1 SCCS comment

2 Despite the mentioned limitations regarding the sensitivity of the analytical method in terms

of LOQ, the estimated lower and upper bound values indicate that there was a certain level of Ti present in the epidermis and dermis layers of the skin (Table 11), indicating potential absorption of the nanoparticles through the skin.


6


Furthermore, the provided TEM images of skin sections show dark spots in several places
below stratum corneum (see a typical example in Figure 10 below). No information is provided
on the chemical identity of these spots. This information is needed (e.g. via SEM or TEM
coupled with EDX) to exclude the possibility that these are TiO₂ nanoparticles to support the
lack of dermal absorption of Eclipse 70 nanoparticles.

12

13 Figure 10: TEM Image of skin section

Dosed Group - Cell 2





3.3 EXPOSURE ASSESSMENT

3.3.1 Function and uses

Provided by the Applicant:

8 In the EU, titanium dioxide (nano form) is approved for use as an UV-filter in a concentration 9 up to 25% in cosmetic products. The substance is regulated in Annex VI, entry 27a of the 10 Cosmetics Regulation. The maximum use concentrations of Eclipse 70 in cosmetic sun 11 protection factor (SPF) products are presented in **Table 12**.

12

1 2

3 4

5 6

7

13 **Table 12:** Maximum concentrations of Eclipse 70 in cosmetic products

Product category	Product types	Maximum use (% w/w) in finished products
Sun protection factor (SPF) products (ingredient used as UV-filter)		
Sun care cosmetics	Face sun protection - lotion/cream (includes all face creams with SPF)	10
	Body sun protection - lotion/cream	10
	Make-up: Liquid foundation with SPF	10

14 15

16

Ref.: 0. TM_Eclipse 70 DOSSIER_06Aug23.pdf

17 **3.4 TOXICOLOGICAL EVALUATION**

18

19 The toxicological studies provided in the submission relate to oral absorption, acute toxicity, 20 skin/eye irritation, skin sensitisation, repeated dose toxicity, mutagenicity/genotoxicity, and photo-induced toxicity of titanium dioxide. Also, the lack of studies on reproductive and 21 developmental toxicity and carcinogenicity was indicated, with inconclusive reports on dermal 22 23 carcinogenicity. It was also mentioned that inhalation is not a relevant route of exposure for 24 Eclipse 70. The submission also contained hazard profiles of the three individual coating 25 materials to regard that they do not affect the particle properties or raise additional safety 26 concerns. 27

28 SCCS comment

The SCCS has noted that, with the exception of a dermal absorption study, the provided toxicological data mainly relate to uncoated nanoparticles of titanium dioxide, and not to Eclipse 70 as a whole entity (i.e. inclusive of the composite coating). The provided toxicological studies are therefore not discussed in detail in this Opinion because it is not possible to relate the information to Eclipse 70.

34

In the absence of specific toxicological data on Eclipse 70, the SCCS considers that it is not possible to derive a meaningful conclusion on the (lack of) toxicological hazard of Eclipse 70 without a clear evidence to demonstrate that: 1) Eclipse 70 nanoparticles have a similar physicochemical profile to other TiO_2 nanomaterials already assessed by the SCCS; 2) the composite coating is stable for the duration of the product shelf life; and 3) that there is no dermal absorption of Eclipse 70 nanoparticles.

41 42

43 **Information provided by the Applicant on individual components of the coating** 44

45 Aluminium hydroxide

Aluminium hydroxide is included in the EU CosIng database as a cosmetic ingredient. However, it is not regulated as such in any of the Annexes of the Cosmetics Regulation, and

48 therefore its safety has not been assessed either as a colorant, preservative, or UV-filter (EC

1 CosIng, 2023). The material has not been evaluated by the SCCS as a coating material on 2 any nanomaterial. As per the Cosmetic Ingredient Review (CIR)'s Expert Panel report, an 3 orally administered aluminium in aluminium hydroxide has low bioavailability (<0.01%) and 4 is excreted primarily in the faeces. The systemically absorbed aluminium in aluminium 5 hydroxide is excreted primarily in the urine (CIR, 2016). Dermal absorption was calculated 6 from an exposure study with female volunteers after application of antiperspirant per axilla. 7 The antiperspirant contained aluminium chlorhydrate which had been doped with radioactive 8 26Al and the volunteers were biomonitored for 26Al in 24 hour-urine. The study result yielded 9 an overall percentage of bioavailable Al of 0.00192% (SCCS, 2023). Aluminium hydroxide can be considered to be of low acute oral toxicity, based on an oral LD50 value of >2000 10 mg/kg bw in rats study. In rabbits' skin and eye irritation studies, undiluted aluminium 11 12 hydroxide was determined to be non-irritating to skin but slightly irritating to eyes. In a guinea 13 pig maximization test (GPMT), there was no skin sensitization reactions reported for 14 aluminium hydroxide (ECHA, 2023c) There were no effects on immunological parameters in 15 humans when orally administered with aluminium hydroxide (equal to 59 mg Al) 3 times daily 16 for 6 weeks (CIR, 2016). Considering the available genotoxicity data, the SCCS was of the 17 opinion that under the scenarios of dermal exposure in cosmetics, aluminium is not likely to 18 pose a risk of genotoxic effects (SCCS, 2023). There was no indication of carcinogenicity at 19 dietary doses up to 850 mg Al/kg bw/day in animal studies, and the SCCS considered that 20 carcinogenicity is not expected at Al exposure levels that are achieved via cosmetic use 21 (SCCS, 2023). In an oral reproductive toxicity study conducted with aluminium salts in mice, 22 rabbits and dogs, testicular toxicity, decreased sperm quality, decrease of testicular weigh, degeneration of germinal epithelium and reduced fertility were observed. No effects on male 23 24 fertility were observed in one rat study where aluminium nitrate was administered by gavage, 25 however, histopathology examination data of testes was not provided for this study. No 26 effects on female fertility were seen in rats after exposure for two weeks before mating and 27 during gestation to aluminium nitrate by gavage or dissolved in drinking water (EFSA, 2008). 28 In developmental toxicity studies in mice and rats, there were no significant maternal or 29 developmental toxicity effects reported in animals orally administered up to 300 mg/kg 30 bw/day aluminium hydroxide (103.8 mg Al/kg bw/day) and 768 mg/kg bw/day aluminium 31 hydroxide (266 mg Al/kg bw/day), respectively (ECHA, 2023c). Effects of oral aluminium 32 exposure (as lactate or chloride) on brain development have been studied in mice. LOAELs 33 for impaired performance of reflexes and simple behaviours in the offspring ranged from maternal doses of 50 to 500 mg Al/kg bw/day. In one study, NOAELs of 10 mg Al/kg bw/day 34 35 in the mother during pregnancy and 42 mg/ kg bw/day during lactation could also be identified. However, in another study performed by the same group of researchers, with 36 37 administration of aluminium lactate from conception throughout the whole lifespan at 100 38 mg/kg bw/day no clear signs of neurotoxicity were observed in the same strain of mice. The 39 European Food Safety Authority (EFSA) expert panel concluded that a value of 1 mg Al/kg bw/week, representing a rounded value between the Tolerable Weekly Intakes (TWIs) 40 provided by using the LOAEL 50 mg Al/kg bw/day and NOAEL 10 mg Al/kg bw/day 41 approaches, should be established as the TWI (EFSA, 2008). In a recent drinking water 42 43 developmental and chronic neurotoxicity study, the rats were exposed to aluminium citrate 44 (30, 100 and 300 mg Al/kg bw/day), one of the more soluble aluminium compounds. 45 Aluminium citrate was generally well tolerated in the dams at all doses, except the high dose 46 (300 mg Al/kg bw/day) where diarrhoea occurred in 8 of the treated dams. The developmental 47 toxicity NOAEL 30 mg AI/kg bw/day was reported, based on reported treatment related renal 48 damage and reduced grip strength in the pups (Poirier et al., 2011, SCCS, 2022). The 49 maternal toxicity NOAEL can be considered as 300 mg Al/kg bw/day. The SCCS in its recent 50 opinion on the safety of aluminium in cosmetic products, derived the systemic NOAEL 51 (NOAELsys) as 180 µg Al/kg bw/day from Poirier et al. study NOAEL, after adjustment for the 52 rat oral bioavailability (0.6%) of aluminium citrate (SCCS, 2023). Aluminium hydroxide was 53 reported to be used in leave-on products up to 10.1% (in eye products) and in rinse-off products up to 8.8% (in oral hygiene products). The CIR Expert Panel concluded that 54 55 aluminium hydroxide is safe in the present practices of use and concentration described in its 56 2016 safety assessment (CIR, 2016). 57

1 Sodium myristoyl sarcosinate (SMS)

2 Sodium myristoyl sarcosinate (SMS) is included in the EU CosIng database as a cosmetic 3 ingredient. It is not regulated as such in any of the Annexes of the Cosmetics Regulation, and 4 therefore its safety has not been assessed either as a colorant, preservative, or UV-filter (EC, 5 2023). The material has so far not been evaluated by the SCCS as a coating on any 6 nanomaterial. The following provides a short summary of the toxicokinetic and toxicological 7 information available for SMS. Most of the information has been generated for the close 8 structural analogue sodium lauroyl sarcosinate (SLS) The acute oral LD50 values for sodium 9 lauroyl sarcosinate (SLS) ranged from 2000 to >5000 mg/kg bw in rodents. The acute dermal 10 LD50 value for SMS was >2000 mg/kg bw in rats. The acute inhalation LC50 value for SLS 50 to 500 mg/m3 in rats (CIR, 2001, 2021). This information suggests SMS to be of low acute 11 12 oral and dermal toxicity. A formulation containing 30% SMS was not irritating to rabbit skin 13 (CIR, 2021). In a Bovine Corneal Opacity and Permeability (BCOP) test, a 20% SMS solution 14 in physiological saline was considered severely irritating to corrosive. A mixture of 30% SMS 15 and sodium myristate was severely irritating to rabbit eyes and considered a primary eye 16 irritant (CIR, 2021). SMS did not exhibit peptide reactive properties in the Direct Peptide 17 Reactivity Assay (DPRA) according to the OECD Test Guideline 442C. SMS induced luciferase 18 activity in LuSens cells in the LuSens assay according to the OECD Test Guideline 442D. SMS 19 did not induce dendritic cell activation in the Human Cell Line Activation Test (h-CLAT) 20 according to the OECD Test Guideline 442E (ECHA, 2023c). In a GPMT, there was no skin sensitization response following exposure to 5% SLS, a structural analogue of SMS (ECHA, 21 22 2023d). In a human repeat-insult patch test (HRIPT), 5% SLS, a structural analogue of SMS was not assessed to be a skin sensitiser (CIR, 2001). Considering the overall weight of 23 24 evidence, SMS is not considered to be a skin sensitiser. 25

26 In a subchronic oral toxicity study conducted in rats, the animals were orally administered 27 the structural analogue SLS at dose levels of 0, 30, 100 or 250 mg/kg bw/day for 90 days. 28 The NOAEL and LOAEL were established at 100 and 250 mg/kg bw/day, respectively (CIR, 29 2021). In a 2-year chronic dietary toxicity study conducted in rats, the animals were fed SLS 30 at the dose levels of 0, 0.05, 0.2 and 1% (equivalent to 0, 39.4, 157.8 and 789 mg/kg bw/day 31 for 2 years (CIR, 2001, US EPA, 1988). The low dose group was fed 0.05% SLS in the daily 32 diet for the first 6 months of the study and 2% SLS in the diet (equivalent to 1578 mg/kg 33 bw/day) for the remaining 18 months. At 1, 3 and 6 months, no significant differences were 34 observed in lesions, fertility, mortality, haematology, or body weight gain between rats of the control and treated groups. At 24 months, the only consistent difference that could be 35 36 attributed to the test substance was minor hyperplasia of the stratified squamous epithelium with excess keratin formation of the cardiac mucosa of the stomach in rats receiving the 37 38 highest exposure to the test substance, 0.05% dose group (2% in the diet after 6 months) 39 and 1% dose group (CIR, 2001). Based on the study results, the NOAEL was established at 40 \geq 2% (equivalent to 1578 mg/kg bw/day) (ECHA, 2023b).

SMS was tested negative in an in vitro genotoxicity battery of tests, i.e., bacterial reverse 41 mutation assay (Ames test), chromosome aberration study in using human lymphocytes and 42 43 mouse lymphoma assay (ECHA, 2023c). Based on the study results, SMS is not expected to 44 be genotoxic. As per the CIR's Expert Panel report, fatty acyl sarcosines and their salts are 45 not considered likely carcinogens as they and their metabolites "do not belong to any class of 46 compounds that contains a significant number of mutagens or oncogens" (CIR, 2021). 47 Considering the weight of evidence, SMS is not expected to have a carcinogenic potential. In 48 a 2-year chronic dietary toxicity study conducted in rats, the feeding of up to 2% SLS did not 49 adversely affect fertility of rats (CIR, 2021). In two oral pre-natal developmental toxicity studies conducted in rats and rabbits for SLS, there were no developmental or teratogenic 50 51 effects were reported up to highest tested dose levels of 250 and 500 mg/kg bw/day, 52 respectively. The maternal toxicity NOAELs were established at 30 and >500 mg/kg bw/day 53 and the developmental toxicity NOAELs were established at >250 and >500 mg/kg bw/day, 54 respectively (CIR, 2021, ECHA, 2023d). SMS was reported to be used in leave-on products 55 up to 5% (in eye products) and in rinse-off products up to 6%. The CIR Expert Panel concluded 56 that SMS is safe as used in cosmetics when formulated to be nonirritating. 57

The CIR Expert Panel also cautioned that Sarcosinate salts should not be used in cosmetic
 products in which N-nitroso compounds can be formed (CIR, 2021).
 3

4 Dimethicone

5 Dimethicone is included in the EU CosIng database as a cosmetic ingredient. However, it is 6 not regulated as such in any of the Annexes of the Cosmetics Regulation, and therefore its 7 safety has not been assessed either as a colorant, preservative, or UV-filter (EC, 2023). 8 Dimethicone has been evaluated by the SCCS as a coating on nano-forms of titanium oxide (SCCS, 2014). Several acute toxicokinetic studies in dogs, rats, and a monkey reported 9 10 minimal gastrointestinal absorption of dimethicone and up to 99.99% recovery of the administered dose via excretion. In a repeated dose study, beagle dogs were fed 91% 11 12 dimethicone at a dose of 300 mg/kg bw/day for 120 days in the diet. Although one female showed atrophy of the spleen, and another female had slightly reddened rugae near the 13 stomach and mucus in the intestine, dimethicone was not detected in any organs or 14 15 considered absorbed (CIR, 2022).

16 In a dermal absorption study conducted in male rats, an occlusive patch containing [14C] 17 dimethicone was applied to male CD rats for 24 h. radioactivity tracing demonstrated that 70% of the administered dimethicone dose was found on the patch materials, 11.4% was 18 19 present at the site of application, and none was found in the blood. Minimal amounts were 20 found in the faeces (0.01%) and carbon dioxide traps (0.001%) (CIR, 2022). Considering an oral LD50 values of >10000 mg/kg bw in rats, dermal LD50 values of >2000 mg/kg bw in 21 22 rats and rabbits, and inhalation LC50 values of >695 to >11500 mg/m3 in rats, dimethicone 23 is considered to be of low acute oral and dermal toxicity and moderate inhalation toxicity 24 (CIR, 2003, ECETOC, 2003). Most dermal irritation studies using rabbits identified 25 dimethicone as a minimal irritant (CIR, 2003). Most of the eye irritation studies conducted 26 with varying viscosities dimethicone following the Draize protocol revealed transient mild to 27 minimal irritation with transient conjunctival reaction as the most frequently observed 28 adverse effect (CIR, 2003). Conjunctival redness is assumed to be due to the physical effect 29 of the silicone causing disruption of the tear film and hence producing eye dryness (ECETOC, 30 2003).

31 Dimethicone (undiluted and 79%) was not a sensitizer in 4 assays using mice and guinea pigs 32 (CIR, 2003). A 5% dimethicone was not assessed to be a skin irritant or sensitiser in a HRIPT study (CIR, 2003). Oral administration of dimethicone fluids of various viscosities in the diet 33 34 in 28-day and 90-day studies did not result in any systemic toxicologically relevant effects up to highest tested dose, 100000 ppm in diet (equivalent to 18000 mg/kg bw/day for 28 day 35 36 rat study, 4600 to 5300 mg/kg bw/day for 90 day rat studies and 18,800 mg/kg bw/day for 90 day mice study) (ECETOC, 2003, US EPA, 1988). Dimethicone was tested negative in an 37 38 in vitro (Ames test, BALB/C-3T3 mouse cell transformation assay, CHO/HGPRT forward 39 mutation assay and Chinese hamster ovary (CHO) chromosome aberration assay) and in vivo 40 (mice micronucleus assay) genotoxicity tests (CIR, 2003).

In a 2-year combined chronic toxicity/carcinogenicity study, rats were dosed with 10 cSt dimethicone for 103 weeks. There were no treatment-related macroscopic or microscopic (neoplastic or non-neoplastic) findings at any dose level and a freestanding NOEL in rats was determined to be at the highest tested dose of 1000 mg/kg bw/day (ECETOC, 2003, JECFA, 2011).

In a 26-month dietary carcinogenicity study performed in rats, no toxicologically relevant
treatment-related effects or increased incidences of any non-neoplastic or neoplastic lesions
were reported in females/male animals up to highest tested dimethicone dose of 1742/2055
mg/kg bw/day. The EFSA panel considered 1742/2055 mg/kg bw/day as the study NOAEL
(EFSA, 2020).

In a 76-week carcinogenicity dietary study, mice were orally fed with 91% dimethicone at 0.25% and 2.5% (equivalent to 520 and 5200 mg/kg bw/day) in diet. Another group received a single 0.2 mL subcutaneous injection of dimethicone (201 mg) into the left flank. The study author concluded that there was no treatment-related increase in the incidence of malignant or benign tumours in the mice groups receiving dimethicone by either oral diet or subcutaneous injection. Also, no treatment-related toxic effects were observed (CIR, 2003). In a dermal lifetime carcinogenicity study, mice were treated topically with motor oil with an

unknown amount of dimethicone. No application site dermal neoplasms were microscopically 1 2 confirmed in treated or control mice. Ulceration at the application site was observed in 8% of 3 treated mice compared to 2.6% of control mice. One treated mouse had a palpable skin mass 4 at the application site during week 65, which reverted by week 67. Epidermal hyperplasia at 5 the application site was more evident in treated mice (17/50) than in control mice (1/115), 6 suggesting to the study author slight dermal irritation (CIR, 2003). Overall, the CIR expert 7 panel and EFSA panel concluded that dimethicone is negative in both oral and dermal 8 carcinogenicity studies (CIR, 2003, EFSA, 2020). 9 In a three-generation reproductive toxicity study performed in rats, the animals were fed 0, 10 0.01 or 0.1% dimethicone in the diet (equivalent to 0, 4.5 or 45 mg/kg bw/day). The survival rate of the parent generation offspring was slightly higher in the high dose group as compared 11 12 to controls, but lower in the generation F1 offspring. However, the study report authors 13 considered these findings to be of questionable significance in the absence of other signs of toxicity. No other significant differences were reported. The EFSA panel noted that the study 14 details provided was limited and the highest dose only 45 mg/kg bw/day (EFSA, 2020). In 15 two male rats, reproductive toxicity studies, no treatment-related changes in any of the 16 17 investigated reproductive parameters were reported in either animals orally dosed with 1000 18 mg/kg bw/day or dermally applied with 3000 mg/kg bw/day 350 cSt dimethicone for 4 weeks 19 (ECETOC, 2003). 20 In three prenatal developmental toxicity studies, administration of dimethicone up to 3800 mg/kg bw/day by gavage in rats and dietary dimethicone up to 756 mg/kg bw/day in rabbits 21 22 did not induce significant treatment-related adverse effects in the incidence of external, 23 visceral, or skeletal abnormalities (CIR, 2003, EFSA, 2020). In similar dermal prenatal 24 developmental toxicity studies in rabbits, no treatment related adverse effects were observed

- 25 in the only tested dose, 200 mg/kg bw/day (CIR, 2003). In another developmental toxicity study, cross-linked silicone gel was implanted into rats and rabbits at doses of 3, 10 and 30 26 27 mL/kg bw equivalent to 2.8, 9.5 and 28.5 g/kg bw/day. Based on the absence of treatment related toxicity, parental as well as developmental NOEL was 28.5 g/kg bw (ECETOC, 2003). 28 29 In a prenatal oral gavage developmental toxicity study, rabbits were dosed orally with 10 or 30 350 cSt dimethicone at doses of 0, 33, 300 and 1000 mg/kg bw/day and the NOAEL for 31 developmental toxicity was considered to be 1000 mg/kg bw/day (ECETOC, 2003). Based on 32 the results of the above studies it can be concluded that the potential of dimethicone to be a
- 33 reproductive or developmental toxicant is low.

34 The Joint FAO/WHO Expert Committee on Food Additives (JECFA) established an acceptable 35 daily intake (ADI) level for dimethicone of 0 to 1.5 mg/kg bw/day (only to compounds with a 36 relative molecular mass in the range of 200–300) (CIR, 2003, JECFA, 2011). The EFSA panel established an ADI of 17 mg/kg bw/day for dimethyl polysiloxane (E 900) using the NOAEL 37 38 1742 mg/kg bw/day from 26-month dietary carcinogenicity study (EFSA, 2020).

39 Dimethicone was reported to be used in leave-on products up to 85% and in rinse-off products 40 up to 23.4%. The CIR Expert Panel concluded that dimethicone is safe in cosmetics in the 41 present practices of use and reported concentration ranges when formulated to be non-42 irritating, with the exception that the available data are insufficient to make a determination 43 of safety for use in products that may be incidentally inhaled when applied using airbrush 44 devices (CIR, 2022).

- 45
- 46

47 **SCCS** comment

48 The SCCS has noted the provided information relating to toxicological hazard of the three 49 individual components of the coating. It is worth highlighting that although each of the 50 substances has been noted in CosIng database for use in cosmetic products, none has yet 51 been assessed for safety as a colorant, preservative, or UV-filter, or included in any of the 52 Annexes of the Cosmetic Products Regulation (EC) No 1223/2009.

53

54 The SCCS has also noted that the information relating to sodium myristoyl sarcosinate is 55 mainly derived from studies on a structural analogue - sodium lauroyl sarcosinate. Citing 56 ECHA (2023), it is mentioned that sodium myristoyl sarcosinate was tested negative in an in 57

vitro genotoxicity battery of tests, i.e., bacterial reverse mutation assay (Ames test), mouse

lymphoma assay, and chromosomal aberration study using human lymphocytes. The SCCS
 requires original study reports in this regard to be able to assess the validity and relevance
 of the tests to the current evaluation.

5 Overall, the SCCS considers that the information on toxicological hazard of the individual 6 coating constituents will be useful when uncertainties and data gaps relating to the potential 7 modulation of the properties and toxicokinetic behaviour of TiO₂ nanoparticles have been 8 clarified.

- 9 10
- 11

12 **3.5 SAFETY EVALUATION (INCLUDING CALCULATION OF THE MOS)**

13

14 According to the Applicant:

Eclipse 70 consists of a core titanium dioxide particle (nano form; up to 70% w/w) and three
coating materials, namely, sodium myristoyl sarcosinate (SMS; up to 14% w/w), dimethicone
(up to 10% w/w), and aluminium hydroxide (up to 6% w/w).

18

22

As presented in **Section 3.1** [of the Applicant's submission], Eclipse 70 is a stable coated titanium dioxide particle (nano form), meaning that the core particle and the coating materials can be considered one entity from a toxicological point of view.

As discussed in Section 3.3.1 [of the Applicant's submission], the results from a recent OECD
 Test Guideline 428 compliant dermal absorption study with Eclipse 70 suggests no significant
 absorption through human skin.

26

27 The absorption measured throughout the experiment was below the LOO for all skin layers. 28 The mean total recovery (i.e., 107-113% considering the lower or upper bound) was within 29 the SCCS acceptance criteria of 85-115%. Further, the imaging of the skin sections using TEM 30 analysis did not show any nanoparticles of titanium dioxide beyond the uppermost layers of the stratum corneum. Titanium dioxide (nano form) has an overall low toxicity profile and the 31 32 data available on the three coatings indicates that they do not affect the particle properties or raise additional safety concerns. Given the low skin penetration potential of Eclipse 70 and 33 the overall low toxicity profile of its individual constituents, the calculation of margins of safety 34 35 (MoS) to evaluate its safety when used as a UV-filter at concentrations of up to 10% w/w in 36 dermally applied cosmetic products is not considered necessary. Exposure by the oral and 37 inhalation routes is assumed to be an unlikely under normal and reasonably foreseeable 38 conditions of use.

39 40

41 SCCS comments

The focus of the current submission was to demonstrate that the TiO₂ nanomaterial with the new composite coating could be considered safe on the basis of similarity in terms of physicochemical and toxicokinetic aspects to other TiO₂ nanomaterials that have already been assessed by the SCCS (SCCS/1516/13 - Revision of 22 April 2014).

46

As discussed in previous sections, the available information indicates Eclipse 70 to be most likely outside the physicochemical and toxicokinetic properties of the TiO₂ nanomaterials covered in the SCCS Opinion (SCCS/1516/13 - Revision of 22 April 2014). The SCCS therefore considers that, in the absence of specific toxicological data on Eclipse 70, safety evaluation of Eclipse 70 is not possible - either on the basis of a similarity to the previously assessed TiO₂ nanomaterials, or on the basis of the additional information provided in the current submission.

- 54
- 55
- 56

1 3.6 DISCUSSION

2 3

4

Chemical and physical specifications

5 Chemical composition: The nanomaterial under current evaluation is composed of core TiO₂ 6 nanoparticles that constitute 70% w/w of the material, which is surface coated sequentially 7 with aluminium hydroxide (up to 6% w/w), sodium myristoyl sarcosinate (up to 14% w/w), and dimethicone (up to 10% w/w). This means that, in the final form, Eclipse 70 nanoparticles 8 9 are composed of up to 30% w/w of the coating materials. The information provided on 10 chemical formula, structure and molecular weight for dimethicone (CAS number 63148-62-11 9) needs to be corrected as it relates to another discrete compound 'dimeticone' 12 (octamethyltrisiloxane; CAS Number: 28349-86-2).

13

14 No specific information is provided about the surface characteristics of Eclipse 70. However, 15 from the information provided on coating materials, it can be anticipated that the surface characteristics of fully coated Eclipse 70 would be determined by the outermost layer of 16 17 dimethicone (i.e. the coated nanoparticles will be hydrophobic). Whilst the SCCS agrees that 18 measurement of octanol/water partition coefficient is not applicable to uncoated titanium 19 dioxide particles, Eclipse 70 has a surface coating composed of inorganic/organic substances (resulting in a hydrophobic surface), which may affect partitioning between 20 21 hydrophilic/lipophilic phases. The OECD TG 126 may be followed in this regard to provide 22 hydrophobicity index of Eclipse 70.

- Particle size distribution: The provided information on sample preparation prior to measurement of particle size distribution is limited to a single sentence: "A dispersion of the sample is made in a 10 mL volume of Isopropanol. 2.5 µL of this solution is then deposited in a Silicon Wafer using a Spin Coating technique". Despite the SCCS request for further information, no more details were provided. The SCCS considers the information as inadequate because appropriate sample preparation to achieve adequate dispersion of nanoparticles is crucial for physicochemical characterisation and toxicological testing of
- 31 nanomaterials (SCCS Guidance on Nanomaterials: SCCS/1655/23).
- 32

The SCCS considers that the use of methods based on laser diffraction is only appropriate for larger sized agglomerates/aggregate, and not for particle size measurement of constituent particles in the nano scale.

36

Particle size distribution of Eclipse 70, measured by SEM (sample 2303-E0132782), is also provided but it is not clear how the line is drawn and whether it is based on a mathematical model. It is notable from Figure 7 that the particle size distribution is not completely monomodal. Also some minor XRD peaks have not been identified in the data provided in the submission.

Despite the uncertainty due to the lack of details on particle dispersion, the information provided on particle size distribution measured by electron microscopy shows that median particle size of Eclipse 70 is around 21 nm. Since up to 30% (w/w) of the material is comprised of coating substances, the actual median size of core TiO₂ nanoparticle is most likely below 21 nm. This renders Eclipse 70 outside the particle size range covered in the SCCS Opinion (SCCS/1516/13 - Revision of 22 April 2014):

49

50 "....have a median particle size based on number size distribution of 30 to 100 nm (measured
51 by different methods) as submitted in the dossier, or larger. Thus, whilst primary particle size
52 may be smaller (around 10 nm), the median particle size of TiO₂ nanomaterials in a cosmetic
53 formulation must not be smaller than 30 nm in terms of number-based size distribution".

55 In response to the SCCS request for further information, the Applicant provided explanation 56 that while the coating represents a significant proportion by weight, the overall thickness of 57 the coating layer is only a few nanometers. It was claimed that analysis of the particle size of

1 both untreated and treated particles (using the same method, SEM by number, and the same 2 lot) showed a very comparable D50 (median particle size). In the absence of any supporting 3 data, the SCCS regards the Applicant's narrative statement as unsatisfactory, and maintains 4 the view that the median particle size range of Eclipse 70 is most likely outside that covered 5 in the previous SCCS Opinion (SCCS/1516/13 - Revision of 22 April 2014).

6 7 Aspect ratio: The aspect ratio of the nanoparticles is given but no explanation is provided on 8 how it was determined. In the absence of information on full aspect ratio distribution based 9 on individual particle size measurements, it is not clear if the given aspect ratio is a 10 median/mean value. The SCCS has also noted that the specific surface area of the materials 11 tested for skin penetration is 5.8 times higher than the one reported above (87.6 m^2/g versus 12 15.14 m^2/q). The Applicant needs to confirm which value is correct, or whether they reflect a 13 variation between the two different batches of the material.

14

15 Stability of the coating: The Applicant provided data from a test to indicate stability of the 16 coating. The reported method involved, dispersing, filtering, making a 'press-cake' and 17 dropping 1-2 water droplet on press-cake, and monitoring contact angle at 0 sec, 20 sec, 60 sec, 15 min, 30 min and 45 min. In response to the SCCS request for further information, the 18 19 Applicant explained that the water droplet contact angle test was used to confirm the stability 20 of the surface treatment, even after applying an isopropanol (IPA) washing process. Other hydrophobicity tests were also conducted over a longer period (up to 48 months), which 21 22 demonstrated that the coated TiO_2 remains stable and retains its water resistance properties. 23 The SCCS regards the provided information unsatisfactory because validity and relevance of 24 the used method have not been established in terms of how the measurement of a change in 25 the water contact angle (over short intervals, and an overall short period of time) could be considered to depict long term stability of the coating on the nanomaterial. Similarly, details 26 27 have not been provided on the 'Float' and 'Stir' methods used in the long term tests to enable 28 assessment of their validity and relevance to demonstrate stability of the coating.

29

30 Photocatalytic activity: The SCCS is of the view that where evidence is provided to show that 31 photocatalytic activity remained quenched over a long period of time, it could be considered 32 an indirect way of ascertaining stability of a coating on a photoreactive/photocatalytic 33 nanomaterial. In this regard, the Applicant provided data on photocatalytic activity (Table-9) to indicate that it is below the acceptable level of 10%, compared to the same material without 34 35 surface coating. However, the provided evidence only comprised of plate images without any 36 detail on how photocatalytic activity was measured, calculated, or what it was compared with to conclude that it was within the acceptable limit. 37

38

39 In response to the SCCS request for further information, the Applicant explained that the 40 method outlined in SCCS/1516/13 was followed for testing. The photocatalytic activity was measured on the coated test sample and the non-coated control. Since the activity of the 41 42 coated test sample was below 10% compared to the non-coated control, the Applicant 43 concluded that the photocatalytic activity of the coated material remained quenched. In the 44 absence of detailed information, the SCCS regards the Applicant's narrative statement as 45 unsatisfactory and reiterates that full experimental details of the test should be provided to 46 enable evaluation of the validity of the results.

47

48 Toxicokinetics: Only limited information is provided on toxicokinetics of Eclipse 70. The SCCS 49 regards the Applicant's narrative statement on the stability of the composite coating as 50 unsatisfactory and considers that stability of the composite coating has not been 51 demonstrated either directly (see 3.1.15) or indirectly (see 3.1.17).

52

53 Dermal/percutaneous absorption: Despite the mentioned limitations regarding the sensitivity 54 of the analytical method in terms of LOQ, the estimated lower and upper bound values 55 provided in the submission indicate that there was a certain level of Ti present in the epidermis 56 and dermis layers of the skin, indicating potential absorption of the nanoparticles through the 57 skin.

8

10

13

15

Furthermore, the provided TEM images of skin sections show dark spots in several places below stratum corneum (see a typical example in the Figure below). No information is provided on the chemical identity of these spots. This information is needed (e.g. via SEM or TEM coupled with EDX) to exclude the possibility that these are TiO₂ nanoparticles to support the lack of dermal absorption of Eclipse 70 nanoparticles.

9 Exposure assessment

11 The information provided by the Applicant on exposure assessment is limited to describing 12 the use levels in different cosmetic products

14 <u>Toxicological evaluation</u>

16 <u>Titanium dioxide:</u> The SCCS has noted that, with the exception of a dermal absorption study, 17 the provided toxicological data mainly relate to uncoated nanoparticles of titanium dioxide, 18 and not to Eclipse 70 as a whole entity (i.e. inclusive of the composite coating). The provided 19 toxicological studies are therefore not discussed in detail in this Opinion because it is not 20 possible to relate the information to Eclipse 70.

21

In the absence of specific toxicological data on Eclipse 70, the SCCS considers that it is not possible to derive a meaningful conclusion on the (lack of) toxicological hazard of Eclipse 70 without a clear evidence to demonstrate that: 1) Eclipse 70 nanoparticles have a similar physicochemical profile to other TiO_2 nanomaterials already assessed by the SCCS; 2) the composite coating is stable for the duration of the product shelf life; and 3) that there is no dermal absorption of Eclipse 70 nanoparticles.

28

Individual components of the coating: The SCCS has noted the provided information relating to toxicological hazard of the three individual components of the coating. It is worth highlighting that although each of the substances has been noted in CosIng database for use in cosmetic products, none has yet been assessed for safety as a colorant, preservative, or UV-filter, or included in any of the Annexes of the Cosmetic Products Regulation (EC) No 1223/2009.

The SCCS has also noted that the information relating to sodium myristoyl sarcosinate is mainly derived from studies on a structural analogue – sodium lauroyl sarcosinate. Citing ECHA (2023), it is mentioned that sodium myristoyl sarcosinate was tested negative in an *in vitro* genotoxicity battery of tests, i.e., bacterial reverse mutation assay (Ames test), mouse lymphoma assay, and chromosomal aberration study using human lymphocytes. The SCCS requires original study reports in this regard to be able to assess the validity and relevance of the tests to the current evaluation.

43

Overall, the SCCS considers that the information on toxicological hazard of the individual
 coating constituents will be useful when uncertainties and data gaps relating to the potential
 modulation of the properties and toxicokinetic behaviour of TiO₂ nanoparticles have been
 clarified.

48 <u>Safety evaluation</u>

49

The focus of the current submission was to demonstrate that the TiO₂ nanomaterial with the new composite coating could be considered safe on the basis of similarity in terms of physicochemical and toxicokinetic aspects to other TiO₂ nanomaterials that have already been assessed by the SCCS (SCCS/1516/13 - Revision of 22 April 2014).

54

As discussed in previous sections, the available information indicates Eclipse 70 to be most likely outside the physicochemical and toxicokinetic properties of the TiO₂ nanomaterials covered in the SCCS Opinion (SCCS/1516/13 - Revision of 22 April 2014). The SCCS therefore considers that, in the absence of specific toxicological data on Eclipse 70, safety evaluation of Eclipse 70 is not possible - either on the basis of a similarity to the previously assessed TiO₂ nanomaterials, or on the basis of the additional information provided in the current submission.

8 4. CONCLUSION

 In light of the data provided, does the SCCS consider safe the use of Titanium Dioxide (nano) coated with a combination of w/w 6% Aluminium Hydroxide, 14% Sodium Myristoyl Sarcosinate and 10% Dimethicone, for use as UV filter in dermally applied cosmetic products?

Considering all the provided information, the SCCS is of the view that there are a number of uncertainties and data gaps that do not allow a conclusion on the safety of titanium dioxide (nano) coated with a combination of w/w 6% aluminium hydroxide, 14% sodium myristoyl sarcosinate and 10% dimethicone (Eclipse 70) - either on the basis of a similarity to the TiO_2 nanomaterials previously assessed by the SCCS, or on the basis of the additional information provided in the current submission.

Does the SCCS have any further scientific concerns regarding the use of Titanium
 Dioxide (nano) coated with the above-mentioned materials when used as UV-filter in
 dermally applied cosmetic products?

The provided information has not demonstrated a similarity of the titanium dioxide with the above-mentioned composite coating (Eclipse 70) to other TiO₂ nanomaterials assessed in the previous SCCS Opinion (SCCS/1516/13 - Revision of 22 April 2014) in terms of physicochemical characteristics, stability of the coating, and the lack of dermal absorption of the nanoparticles. If these aspects cannot be addressed, additional data on physicochemical, toxicological and exposure aspects specifically relating to the nanomaterial under evaluation (Eclipse 70) will be needed to conclude on the safety of its use in cosmetic products.

5. MINORITY OPINION

40 None.

1 6. REFERENCES

2

Brun E, Barreau F, Veronesi G, Fayard B, Sorieul S, Chanéac C, Carapito C, Rabilloud T,
Mabondzo A, Herlin-Boime N, et al. 2014. Titanium dioxide nanoparticle impact and
translocation through ex vivo, in vivo and in vitro gut epithelia. Part. Fibre Toxicol., 11: 13.

6 Cho WS, Kang BC, Lee JK, Jeong J, Che JH and Seok SH. 2013. Comparative absorption,
7 distribution, and excretion of titanium dioxide and zinc oxide nanoparticles after repeated oral
8 administration. Partic. Fibre Toxicol. 10(1): 1-9.

9 Coméra C, Cartier C, Gaultier E, Catrice O, Panouille Q, El Hamdi S, Tirez K, Nelissen I, 10 Théodorou V and Houdeau E. 2020. Jejunal villus absorption and paracellular tight junction 11 permeability are major routes for early intestinal uptake of food-grade TiO 2 particles: an in 12 vivo and ex vivo study in mice. Partic. Fibre Toxicol., 17(1): 1-15.

Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment (COT).
 2022. Interim position paper on titanium dioxide. <u>2021 - statements and position papers</u>
 Committee on Toxicity (food.gov.uk) (accessed in May 2023).

16 Cosmetic Ingredients Review (CIR) Expert Panel. 2001. Final report on the safety assessment 17 of cocoylsarcosine, lauroyl sarcosine, myristoyl sarcosine, oleoyl sarcosine, stearoyl 18 sarcosine, sodium cocoylsarcosinate, sodium lauroyl sarcosinate, sodium myristoyl 19 sarcosinate, ammonium cocoyl sarcosinate, and ammonium lauroyl sarcosinate. Int. J. 20 Toxicol. 20 Suppl 1: 1-14.

Cosmetic Ingredients Review (CIR) Expert Panel. 2003. Final report on the safety assessment of stearoxy dimethicone, dimethicone, methicone, amino bispropyl dimethicone, aminopropyl dimethicone, amodimethicone, amodimethicone hydroxystearate, behenoxy dimethicone, C24-28 alkyl methicone, C30-45 alkyl methicone, C30-45 alkyl dimethicone, cetearyl methicone, cetyl dimethicone, dimethoxysilyl ethylenediaminopropyl dimethicone, hexyl methicone, hydroxypropyldimethicone, stearamidopropyl dimethicone, stearyl dimethicone, stearyl methicone, and vinyldimethicone. Int. J. Toxicol. 22 Suppl 2:11-35.

28 Cosmetic Ingredients Review (CIR) Expert Panel. 2016. Safety assessment of alumina and 29 aluminum hydroxide as used in cosmetics. Int. J. Toxicol. 35(3 suppl): 16S-33S.

Cosmetic Ingredients Review (CIR) Expert Panel. 2021. Amended safety assessment of fatty
 acyl sarcosines and sarcosinate salts as used in cosmetics. Int. J. Toxicol. 40(2_suppl): 117S-

32 133S.

Cosmetic Ingredients Review (CIR) Expert Panel. 2022. Amended safety assessment of
 dimethicone, methicone, and substituted-methicone polymers as used in cosmetics, April 19,
 2022. FAR Methicones 032022.pdf (cir-safety.org).

Duan Y, Liu J, Ma L, Li N, Liu H, Wang J, Zheng L, Liu C, Wang X, Zhao X, Yan J, Wang S,
Wang H, Zhang X, Hong F. 2010. Toxicological characteristics of nanoparticulate anatase
titanium dioxide in mice. Biomaterials. 31(5): 894-9.

European Chemicals Agency (ECHA). 2023a. REACH registration of titanium dioxide (CAS
number: 13463-67-7; EC number: 236-675-5). <u>https://echa.europa.eu/da/registration-</u>
<u>dossier/-/registereddossier/15560</u> (accessed in April 2023).

European Chemicals Agency (ECHA). 2023b. REACH registration of sodium n-methyl-n-(1 oxotetradecyl)aminoacetate (CAS number: 30364-51-3; EC number: 250-151-3).
 <u>https://echa.europa.eu/it/registration-dossier/-/registered-dossier/26759</u> (accessed in April
 2023).

46 European Chemicals Agency (ECHA). 2023c. REACH registration of sodium n-47 lauroylsarcosinate (CAS number: 137-16-6; EC number: 205-281-5)

48 <u>https://echa.europa.eu/it/registration-dossier/-/registereddossier/14123</u> (accessed in April
 49 2023).

- 1 European Chemicals Agency (ECHA). 2023d. REACH registration of aluminium hydroxide (CAS
- 2 number: 21645-51-2; EC number: 244-492-7). https://echa.europa.eu/de/registration-
- 3 <u>dossier/-/registereddossier/15529</u> (accessed in April 2023).
- 4 European Chemicals Agency (ECHA). RAC. 2017. Opinion proposing harmonised classification
- 5 and labelling at EU level of titanium dioxide (EC Number: 236-675-5; CAS Number: 13463-
- 6 67-7). Report No. CLH-O-0000001412-86-163/F, ECHA Committee for Risk Assessment
- 7 (RAC). <u>https://echa.europa.eu/documents/10162/682fac9f-5b01-86d3-2f70-3d40277a53c2</u>
- 8 European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC). 2011. Linear 9 polydimethylsiloxanes, CAS No. 63148-62-9, JACC No 55 (2nd edition).
- 9 polydimethylsiloxanes, CAS No. 63148-62-9, JACC No 55 10 https://www.ecetoc.org/wpcontent/uploads/2014/08/JACC-055-Linear-
- 11 Polydimethylsiloxanes-CAS-No.-63148-62-9-Second-Edition.pdf
- EC Cosing. 2023. European Commission database for information on cosmetic substances and
 ingredients: substance: 2-phenoxyethanol (CAS No.122-99-6), on European Commission
 (EC).
- https://ec.europa.eu/growth/toolsdatabases/cosing/index.cfm?fuseaction=search.details_v2
 <u>&id=28157</u> (accessed in May 2023).
- 17 European Food Safety Authority (EFSA). 2008. Safety of aluminium from dietary intake,
- 18 Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Food
- 19 Contact Materials (AFC). EFSA Journal. 754: 1-34.
- European Food Safety Authority (EFSA). 2016. Re-evaluation of titanium dioxide (E 171) as a food additive. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS).
- 22 EFSA Journal 14(9):4545, 83 pp.
- European Food Safety Authority (EFSA). 2020. Re-evaluation of dimethyl polysiloxane (E 900)
 as a food additive. EFSA Journal. 18(5): 6107.
- European Food Safety Authority (EFSA). 2021. Safety assessment of titanium dioxide (E171)
 as a food additive. EFSA Journal 19(5):6585, 130 pp.
- Food Standards Australia New Zealand (FSANZ). 2022. Titanium dioxide as a food additive
 (accessed in May, 2023).
- 29 Furukawa F, Doi Y, Suguro M, Morita O, Kuwahara H, Masunaga T, Hatakeyama Y, Mori F.
- 2011. Lack of skin carcinogenicity of topically applied titanium dioxide nanoparticles in the 31 mouse. Food Chem Toxicol. 49: 744-749.
- Geraets L, Oomen AG, Krystek P, Jacobsen NR, Wallin H, Laurentie M, Verharen HW, Brandon EF and de Jong WH. 2014. Tissue distribution and elimination after oral and intravenous administration of different titanium dioxide nanoparticles in rats. Partic. Fibre Toxicol., 11(30): 1-21.
- Health Canada. 2022. State of the science of titanium dioxide (TiO₂) as a food additive. Food
 Directorate, Health Canada, Ottawa, Canada. Available at:
 https://www.canada.ca/en/healthcanada/services/foodnutrition/reports-
- 39 <u>publications/titanium-dioxide-food-additive-sciencereport.html</u> (accessed in October 2022).
- Heo MB, Kwak M, An KS, Kim HJ, Ryu HY, Lee SM, Song KS, Kim IY, Kwon JH and Lee TG.
 2020. Oral toxicity of titanium dioxide P25 at repeated dose 28-day and 90-day in rats. Part
 Fibre Toxicol. 17, 34.
- 43 Heringa MB, Peters RJB, Bleys RLAW, Van Der Lee MK, Tromp PC, Van Kesteren PCE, Van
- 44 Eijkeren JCH, Undas AK, Oomen AG and Bouwmeester H. 2018. Detection of titanium particles 45 in human liver and spleen and possible health implications. Partic. Fibre Toxicol., 15(1):15.
- Hu R, Gong X, Duan Y, Li N, Che Y, Cui Y, Zhou M, Liu C, Wang H, Hong F. 2010.
 Neurotoxicological effects and the impairment of spatial recognition memory in mice caused
 by exposure to TiO₂ nanoparticles. Biomaterials. 31(31): 8043-50.
- Janer G, Del Molino EM, Fernández-Rosas E, Fernández A and Vázquez-Campos S. 2014. Cell
- 50 uptake and oral absorption of titanium dioxide nanoparticles. Tox. Let., 228(2): 103-110.

- 1 Joint FAO/WHO Expert Committee on Food Additives (JECFA). 2011. Safety evaluation of
- 2 certain food additives and contaminants: prepared by the Seventy-fourth meeting of the
- 3 JECFA, WHO technical report series: 966.
- Jones K, Morton J, Smith I, Jurkschat K, Harding AH and Evans G. 2015. Human in vivo and
 in vitro studies on gastrointestinal absorption of titanium dioxide nanoparticles. Tox. Let.,
 233(2): 95-101.
- Kirkland D, Aardema MJ, Battersby RV, Beevers C, Burnett K, Burzlaff A, Czich A, Donner M,
 Fowler P, Johnston HJ. 2022. A weight of evidence review of the genotoxicity of titanium
 dioxide (TiO₂). Reg. Tox. and Pharm. 136: 105263.
- Kravcenko K. 2023a. In vitro percutaneous absorption of amino acid treated nano-titanium
 dioxide with dimethicone (ECLIPSE70-D13-NT-77891) in a single representative cosmetic
 formulation through human skin (OECD 428 & SCCS). Charles River Laboratories Edinburgh
 Limited. Elphinstone Research Centre Tranent, East Lothian, EH33 2NE, United Kingdom; Test
 facility study No. 789450.
- Kravcenko K. 2023b. Vizualization of amino acid treated nano-titanium dioxide with
 dimethicone (ECLIPSE70-D13-NT-77891) in human skin following in vitro percutaneous
 absorption. Charles River Laboratories Edinburgh Limited. Elphinstone Research Centre
 Tranent, East Lothian, EH33 2NE, United Kingdom; Test facility study No. 789455.
- Poirier J, Semple H, Davies J, et al. 2011. Double-blind, vehicle-controlled randomized twelvemonth neurodevelopmental toxicity study of common aluminum salts in the rat. Neuroscience.
 2011; 193: 338-362.
- 22 Sagawa Y, Futakuchi M, Xu J, Fukamachi K, Sakai Y, Ikarashi Y, Nishimura T, Suzui M, Tsuda
- 23 H and Morita A. 2012. Lack of promoting effect of titanium dioxide particles on chemically-
- induced skin carcinogenesis in rats and mice, J. Toxicol. Sci. 37(2): 317-327.
- 25 Scientific Committee on Consumer Safety (SCCS). 2014. Opinion on titanium Dioxide (nano 26 form) COLIPA n° S75- Revision. Report No. SCCS/1516/13, Scientific Committee on
- 27 Consumer Safety, European Commission
- 28 <u>https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/sccs_o_136.pdf</u>
- SCCS. 2018. Opinion on titanium dioxide (nano form) coated with cetyl phosphate,
 manganese dioxide or triethoxycaprylylsilane as UV-filter in dermally applied cosmetic. Report
- 31 No. SCCS/1580/16, Scientific Committee on Consumer Safety
- 32 <u>https://health.ec.europa.eu/system/files/2018-07/sccs_o_202_0.pdf</u>
- SCCS. 2020. Opinion on titanium dioxide (TiO₂) used in cosmetic products that lead to
 exposure by inhalation. Scientific Committee on Consumer Safety, European Commission.
 https://health.ec.europa.eu/system/files/2021-11/sccs 238.pdf
- 36 SCCS. 2023a. The SCCS notes of guidance for the testing of cosmetic ingredients and their
- 37 safety evaluation 12th revision. Report No. SCCS/1647/22
- 38 https://health.ec.europa.eu/system/files/2023-05/sccs_o_273.pdf
- 39 SCCS. 2023b. SCCS opinion on the safety of aluminium in cosmetic products- submission III.
- 40 Report No. SCCS/1644/22, Scientific Committee on Consumer Safety
- 41 <u>https://health.ec.europa.eu/system/files/2023-03/sccs_o_266_0.pdf</u>
- Shi J, Han S, Zhang J, Liu Y, Chen Z, Jia G. 2022. Advances in genotoxicity of titanium dioxide
 nanoparticles in vivo and in vitro. NanoImpact. 25: 100377.
- Talamini L, Gimondi S, Violatto MB, Fiordaliso F, Pedica F, Tran NL, Sitia G, Aureli F, Raggi A,
 Nelissen I and Cubadda F. 2019. Repeated administration of the food additive E171 to mice
 results in accumulation in intestine and liver and promotes an inflammatory status.
 Nanotoxicology, 13(8): 1087-1101.
- 48 US Environmental Protection Agency (US EPA). 1988. Recommendations for and 49 documentation of biological values for use in risk assessment, EPA/600/6-87/008 (NTIS 50 PB88179874), 1988, accessed at

- 1 <u>https://ordspub.epa.gov/ords/eims/eimscomm.getfile?p_download_id=471813</u>
- 2 Wang J, Zhou G, Chen C, Yu H, Wang T, Ma Y, Jia G, Gao Y, Li B, Sun J and Li Y. 2007. Acute
- 3 toxicity and biodistribution of different sized titanium dioxide particles in mice after oral
- 4 administration. Tox. Let., 168(2): 176-185.

5 Wani MR, Shadab G. 2020. Titanium dioxide nanoparticle genotoxicity: A review of recent in 6 vivo and in vitro studies. Toxicol. Ind. Health. 36(7): 514-530.

Warheit DB, Boatman R, Brown SC. 2015. Developmental toxicity studies with 6 forms of
titanium dioxide test materials (3 pigment-different grade & 3 nanoscale) demonstrate an
absence of effects in orallyexposed rats. Regul. Toxicol. Pharmacol. 73(3): 887-96.

- 10 Xu J, Sagawa Y, Futakuchi M, Fukamachi K, Alexander DB, Furukawa F, Ikarashi Y, Uchino T,
- 11 Nishimura T, Morita A, Suzui M, Tsuda H. 2011. Lack of promoting effect of titanium dioxide
- 12 particles on ultraviolet Binitiated skin carcinogenesis in rats, Food Chem Toxicol. 49: 1298-
- 13 1302.